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ABSTRACT: A series of imidazo[1,2-b]pyridazin-8-amine
kinase inhibitors were discovered to allosterically inhibit the
endoribonuclease function of the dual kinase-endoribonu-
clease inositol-requiring enzyme 1α (IRE1α), a key
component of the unfolded protein response in mammalian
cells and a potential drug target in multiple human diseases.
Inhibitor optimization gave compounds with high kinome
selectivity that prevented endoplasmic reticulum stress-induced IRE1α oligomerization and phosphorylation, and inhibited
endoribonuclease activity in human cells. X-ray crystallography showed the inhibitors to bind to a previously unreported and
unusually disordered conformation of the IRE1α kinase domain that would be incompatible with back-to-back dimerization of
the IRE1α protein and activation of the endoribonuclease function. These ﬁndings increase the repertoire of known IRE1α
protein conformations and can guide the discovery of highly selective ligands for the IRE1α kinase site that allosterically inhibit
the endoribonuclease.
■ INTRODUCTION
The dual kinase-endoribonuclease inositol-requiring enzyme
1α (IRE1α; ERN1) is a central and conserved component of
the unfolded protein response (UPR) activated by eukaryotic
cells in reaction to endoplasmic reticulum (ER) stress, caused
by an excess of misfolded proteins in the ER lumen.1,2
Activation of the UPR reduces protein translation and
increases the protein-folding capacity. If this initial response
does not alleviate ER stress, prolonged activation of the UPR
signaling network leads to apoptosis. Thus, the balance of
downstream anti- and proapoptotic signaling pathways
activated by the UPR determines cell fate in the presence of
acute or chronic proteotoxic stress.
IRE1α is an ER membrane resident protein with serine/
threonine kinase and endoribonuclease (RNase) functions
contained in its cytosolic domain.3 The accumulation of
unfolded or misfolded proteins in the ER lumen triggers
oligomerization of IRE1α and kinase autophosphorylation,
resulting in activation of the RNase.4−6 The RNase speciﬁcally
cleaves the messenger RNA (mRNA) coding for the unspliced
transcription factor X-box protein 1 (XBP1u) to remove a 26
base pair intron, and subsequent ligation produces the mRNA
of the active, spliced form (XBP1s) of the transcription factor.7
XBP1s-dependent transcription includes upregulation of ER-
resident molecular chaperones required to relieve aberrant
protein folding.8 In contrast, nonspeciﬁc cleavage of other
mRNAs localized at the ER membrane by IRE1α RNase
(termed regulated IRE1-dependent decay) is proposed to exert
an apoptotic eﬀect.9 Additionally, the interaction of TRAF2
with oligomerized phospho-IRE1α elicits signaling through the
JNK/c-JUN axis, independent of IRE1α RNase activity.10 In
mammalian cells, IRE1α functions with the transcriptional
repression and regulation of apoptosis eﬀected by the other
UPR elements, ATF6 and PERK, to alleviate ER stress or to
direct cell death.1,2
Dysregulation of IRE1α-XBP1s signaling is implicated in a
number of human diseases, including cancer, diabetes,
lipidemia, inﬂammatory disease, and neurodegeneration.1,11
Signaling through IRE1α-XBP1s has been proposed as
important for the survival of myeloma cells, as well as breast
and prostate cancers.12−14 Recently, in an ovarian cancer in
vivo model, XBP1s function has been shown to suppress
proper presentation of tumor-associated antigens by tumor-
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inﬁltrating dendritic cells, thus determining the degree of T-
cell antitumor immune response and suggesting that
modulation of XBP1 splicing in normal tissue may be an
alternative approach for an anticancer therapy.15
There is a clear need for selective chemical tools to explore
the consequences of IRE1α inhibition by diﬀerent mechanisms
in cancer and nontransformed cells and to study the IRE1α-
XBP1s pathway in other human diseases. Given the diverse
nature of IRE1α signaling outputs, inhibitors targeting the
kinase or RNase functions, or both, may have diﬀerent
consequences for cell fate, which may further vary according to
cell context. Reversible covalent binders targeting the RNase
active site directly have been reported from a salicylaldehyde
scaﬀold16−18 and have been shown to inhibit cancer cell
growth.18−20 The pharmacology of inhibitors binding at the
IRE1α kinase site is complicated by the possibility of allosteric
inhibition or activation of the RNase function depending on
the conformation of the kinase domain and oligomerization
state that is stabilized.21 Allosteric inhibition of the RNase
function has been associated with type II kinase site ligands
that bind the DFG-out conformation of the kinase21 or other
compounds that displace the αC-helix of the kinase from the
active conformation.22−24 While a series of highly selective,
kinase site binding, allosteric inhibitors of IRE1α RNase have
shown no direct cytotoxic eﬀect on a range of cancer cell
lines,23 compounds with this proﬁle remain of interest for
other therapeutic approaches that target nonmalignant cells.25
In contrast to type II and αC-helix displacing scaﬀolds,
reported type I IRE1α kinase site ligands promote dimerization
and activate the RNase function.6,21 The identiﬁcation of new
activators and inhibitors of IRE1α RNase and understanding
the allosteric mechanisms linking the kinase and RNase sites
are therefore of continued importance for the development of
new therapeutics.
We previously described the type I imidazo[1,2-b]pyridazine
kinase inhibitor 1 (Figure 1) that allosterically activates IRE1α
endoribonuclease in vitro.6 While screening chemical scaﬀolds
based on 1, we unexpectedly discovered the related type I
imidazo[1,2-b]pyridazin-8-amine 2 (Figure 1A) to be an
inhibitor of both the kinase and RNase functions of IRE1α.
In this study, we show how 2 and more potent analogues bind
to a previously undescribed inactive conformation of
monomeric IRE1α involving major rearrangements of key
secondary structure in the kinase domain, including disorder-
ing of the αC-helix and disruption of the hydrophobic spine of
the protein, which together confer high IRE1α kinase binding
selectivity and inhibition of both kinase and RNase functions.
We conﬁrm that these allosteric modulators disrupt all
downstream signaling through IRE1α in human cells, thus
validating targeting of this unusual binding mode as a new way
to generate selective and cell active inhibitors of IRE1α.
■ SYNTHETIC CHEMISTRY
We established short synthetic routes to prepare analogues of 2
using the diﬀerential reactivity of the polyhalogenated
imidazo[1,2-b]pyridazine 3 (Scheme 1). Selective displace-
men t o f the 8 -b romo subs t i t u en t in t roduced
(cyclopropylmethyl)amine and was followed by Suzuki
reactions of the 3-bromo group of 4 to give compounds 5−
12. The 6-chloro substituent of 3 and 4 might be expected to
undergo competing nucleophilic substitution or palladium
insertion but proved notably stable under the conditions
studied.26 To replace the indazol-5-yl substituent of 2 with 2-
(N-phenyl)amino-1H-benzo[d]imidazole, the intermediate 13
was prepared from 5-bromo-2-chloro-1H-benzo[d]imidazole
by displacement of the 2-chloro group with aniline and N-
protection, before palladium-catalyzed installation of the
boronate (Scheme 1). Compound 13 was obtained and used
as a mixture of N-Boc 2-aminobenzimidazole regioisomers,
with complete N-deprotection observed in the subsequent
Suzuki reaction. 2-(Methylamino)benzimidazole 14 did not
require N-protection for successful reaction. Other N-
methylated 2-aminobenzimidazoles 16 and 18 were synthe-
sized from the nitrophenyl boronates 15 and 17, respectively,
by nitro group reduction and condensation with isothiocyana-
tobenzene.27
The synthesis was adapted to vary the 8-amino substituent
of the imidazo[1,2-b]pyridazine by reacting a range of amines
with substrate 3 to give 19−21 and 27−29 (Scheme 2). For
the unsubstituted 1,4-diaminocyclohexanes 22 and 23, N-
protection of the terminal amine, to ensure selectivity, and
higher temperatures were required in the nucleophilic
substitution step. The more elaborate 1,4-diaminocyclohexane
substituents incorporated into 24−26 were made prior to
reaction with 3. Fluorine substituents were introduced into the
2-(N-phenyl)amino-1H-benzo[d]imidazole group starting
from the appropriate ﬂuorinated 4-bromobenzene-1,2-dia-
mines via condensation with isothiocyanatobenzene, and the
route was telescoped to generate compounds 30−32.
■ RESULTS
Compound 2 (Figure 1A and Table 1) was discovered through
screening of type I kinase scaﬀolds related to the IRE1α kinase
inhibitor-RNase activator 16. Unexpectedly, we determined
that while inhibiting the kinase activity with similar potency to
1, compound 2 was an inhibitor of the RNase function in vitro,
Figure 1. (A) Structures of the IRE1α RNase activator 1 and the
structurally related RNase inhibitor 2. (B) Structures of selected
published IRE1α kinase-RNase inhibitors.
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suggesting a diﬀerent allosteric eﬀect on the RNase compared
to typical type I IRE1α kinase inhibitors.21 The small size of 2
compared to reported IRE1α kinase-RNase inhibitors from
type II- or type I-extended scaﬀolds (e.g., KIRA3 and
compound 16, respectively; Figure 1B) was also attractive as
a potential starting point for inhibitor optimization.21,23,24 We
hypothesized that the orientation of 2 within the IRE1α
adenosine 5′-triphosphate (ATP) site would be similar to that
determined for 1 (PDB 4Z7H).6 We anticipated that the key
hinge-binding hydrogen bond from N-1 of the imidazo[1,2-
b]pyridazine would be maintained and that a new hydrogen
bond could be formed to the hinge region from the 8-amino
group, replacing the CH···O interaction seen for 1. In this
orientation, the indazole substituent would be directed toward
the αC-helix, taking the place of the benzamide moiety in 1,
while the cyclopropylmethyl group would be directed out
toward solvent. The imidazo[1,2-b]pyridazin-8-amine hinge-
binding group has recently been shown to adopt such a
binding mode to the kinase, monopolar spindle 1 (MPS1).28,29
We used in vitro biochemical assays to measure compound
binding and eﬀects on IRE1α autophosphorylation and
endoribonuclease activities, to investigate the structure−
activity relationships around 2 and test the proposed binding
model. Recombinant IRE1α protein corresponding to the
cytoplasmic kinase-endoribonuclease extended (KEN) domain
(G547 IRE1α) was produced separately in phosphorylated and
dephosphorylated states, as conﬁrmed by intact protein mass
spectrometry (MS) (Figure S1).30 We used our previously
described DELFIA format to determine the inhibition of
recombinant IRE1α S274 autophosphorylation.31 To measure
compound binding to IRE1α, we developed a LanthaScreen Eu
Kinase binding FRET assay, which monitored the displace-
ment of an ATP-site tracer. To determine the allosteric eﬀect
of the kinase inhibitors on IRE1α RNase activity, we used a
FRET-based assay to measure the cleavage of a short stem-
loop RNA sequence derived from the endogenous cleavage site
in XBP1u mRNA (Figure S2).21,30
We initially investigated the role of the indazol-5-yl
substituent in 2 (Table 1). The availability and correct
positioning of hydrogen bond donor/acceptor functionality
was critical, with neither the N-methyl (5) nor regioisomeric
(6) analogues showing activity. Only weak inhibition of IRE1α
autophosphorylation in the sensitive DELFIA format was
observed for the indol-5-yl derivative (7). The benzimidazol-5-
yl analogue (8) also inhibited IRE1α autophosphorylation but
showed signiﬁcantly weaker ATP-site binding in the
LanthaScreen assay and no RNase inhibition. For the RNase
assay, this may in part reﬂect the reduced potency of 8
compared to 2. The weak potency for ATP-site binding assay
was unexpected, but based on the promising inhibition of
IRE1α autophosphorylation, we pursued further substitution of
the benzimidazol-5-yl scaﬀold.
We assumed that the indazol-5-yl substituent of 2 potentially
interacted with the same region of the IRE1α active site as the
benzamide of 1, in particular with residues such as D711 from
the DFG motif or K599. Compound 1 also interacted with a
water molecule that was in contact with E612 from the αC-
helix.6 Therefore, we investigated 2-(N-phenyl)amino sub-
stitution of the benzimidazole 8. The 2-(N-phenyl)-
aminobenzimidazole motif is a known isostere for the diaryl
urea motif more commonly found in type II kinase inhibitors,
as it is capable of mimicking the hydrogen-bonding pattern
Scheme 1. Syntheses of Compounds 2−18a
aReagents and conditions: (i) 2-chloroacetaldehyde, EtOH, 50 °C, 21 h, 78%; (ii) N-bromosuccinimide, CH3Cl, 0 °C to room temperature (rt), 16
h, 84%; (iii) cyclopropylmethanamine, tetrahydrofuran (THF), rt, 3 h, 93%; (iv) heteroaryl boronate, Pd(OAc)2, 1,1′-bis(di-tert-
butylphosphino)ferrocene, 2 M Na2CO3, dioxane, 120−135 °C, 15−22 h, 5−51%; (v) (a) PhNH2, 180 °C (microwave), 1 h; (b) (Boc)2O, 4-
dimethylaminopyridine (DMAP), THF, rt, 16 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2·CH2Cl2, 1,4-dioxane, 100 °C, 16 h, 53% over
three steps; (vi) PhNHMe, 180 °C (microwave), 1 h, 86%; (vii) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2·CH2Cl2, 1,4-dioxane, 100 °C, 16 h,
36%; (viii) isothiocyanatobenzene, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), THF, 50 °C, 5 h, 17−45%.
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made by type II urea inhibitors in the inactive DFG-out
conformation of the kinase domain.32 The addition of aryl urea
groups or their isosteres to convert type I kinase inhibitor
scaﬀolds to type II molecules is a well-established approach.33
Gratifyingly, we observed that the 2-(N-phenyl)-
aminobenzimidazole 9 had similar kinase site binding aﬃnity
to 2, and improved on the inhibition of IRE1α RNase activity.
Consistent with a role for the 2-(N-phenyl)aminoimidazole
functionality in forming multiple hydrogen bonds, N-
methylation at any position reduced inhibitory activity (see
10−12).
With two variations of the imidazo[1,2-b]pyridazin-8-amine
core identiﬁed that led to RNase inhibition, the eﬀects of
varying the 8-amino group on potency and physicochemical
properties were studied. The aqueous (aq) buﬀer solubilities of
2 (KSol = 0.8 μM) and 9 (KSol = 2.9 μM) were low, consistent
with their measured lipophilicities (2, LogD7.4 = 3.4; 9, Log
D7.4 = 4.1). We therefore sought to introduce polar or
ionizable groups to improve solubility and hypothesized that
Scheme 2. Syntheses of Compounds 19−32a
aReagents and conditions: (i) amine, THF, rt, 16 h, 60−97%; (ii) heteroaryl boronate, Pd(OAc)2, 1,1′-bis(di-tert-butylphosphino)ferrocene, 2 M
Na2CO3, 1,4-dioxane, 130 °C, 16 h, 4−55%; (iii) tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate, THF, 50 °C, 16 h, quantitative; (iv) HCl, 1,4-
dioxane, rt, 2 h, 99%; (v) (a) LiAlH4, THF, 0 °C to reﬂux, 4 h; (b) ethyl 1,3-dioxoisoindoline-2-carboxylate, Et3N, CH2Cl2, rt, 15 h; (c) 3, Et3N,
1,4-dioxane−dimethyl sulfoxide (DMSO), 100 °C, 22 h, 52% over three steps; (vi) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole,
Pd(OAc)2, 1,1′-bis(di-tert-butylphosphino)-ferrocene, 2 M Na2CO3, 1,4-dioxane, 130 °C, 21 h, then NH2NH2·H2O, 100 °C, 48 h, 34%; (vii)
amine, THF, 50 °C, 16 h, 29−85%; (viii) (a) tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate, Et3N, CH2Cl2, rt, 20 h; (b) HCl−1,4-dioxane,
MeOH, rt, 2 h, 37% over two steps; (ix) 3, Et3N, 1,4-dioxane-DMSO, 50 °C, 23 h, 58%; (x) (a) isothiocyanatobenzene, EDC, THF, 50 °C, 5 h; (b)
(Boc)2O, DMAP, THF, rt, 16 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2·CH2Cl2, 1,4-dioxane, 135 °C, 24 h; (d) 3-bromo-6-chloro-N-((1-
methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine, Pd(OAc)2, 1,1′-bis(di-tert-butylphosphino)-ferrocene, 2 M Na2CO3, 1,4-dioxane,
135 °C, 16 h, 2−5% over four steps.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01721
J. Med. Chem. 2019, 62, 2447−2465
2450
the vector deﬁned by the cyclopropylmethyl group should be
directed toward solvent. Importantly, studies leading to the
IRE1α inhibitor compound 16 (Figure 1B) found that
appending cyclic amine or cyclohexylamine substituents
directed out of the ATP-binding pocket was essential for
achieving high potency.23 Our presumed binding mode of the
core scaﬀolds 2 and 9 oriented the 8-amino substituent in a
similar direction. We investigated a range of substituents,
including cyclic amines analogous to those described in the
development of compound 16, with selected examples
highlighted in Table 2.
Introduction of polar groups generally maintained the dual
kinase-RNase inhibitory proﬁle of the compounds while
enhancing potency. Thus, replacement of the cyclopropyl-
methyl substituent by tetrahydropyran-4-yl resulted in
submicromolar inhibitors of IRE1α RNase function, 19 and
27. Aqueous solubility remained low (19, KSol = 2.2 μM; 27,
KSol = 2.4 μM), but was increased in the basic N-
methylpiperidin-4-yl derivatives 20 (KSol = 58 μM, LogD7.4
= 1.8) and 28 (KSol = 41 μM, LogD7.4 = 2.7), which also
showed improvements in RNase inhibition.
For the 3-(indazol-5-yl) substituted analogues, extension of
the piperidine substituent had a negligible eﬀect on compound
aﬃnity or potency (see 21). However, the trans-1,4-
diaminocyclohexane analogue 22 showed enhanced binding
and RNase inhibition. Notably, N-8-methylation to give 23 led
to loss of activity, consistent with the assumed kinase hinge-
binding role of the 8-amino substituent. Further substitution of
the trans-1,4-diaminocyclohexane group was tolerated, exem-
pliﬁed by 24−26, and led to potent in vitro inhibitors of IRE1α
RNase activity with acceptable aqueous solubility (e.g., 26, KSol
= 80 μM, LogD7.4 = 1.8).
For the 3-(2-(N-phenyl)aminobenzimidazol-5-yl) substi-
tuted compounds, the (N-methylpiperidin-4-yl)methyl ana-
logue 29 provided an enhancement in binding and RNase
inhibitory potency without the need for further substitution.
We examined ﬂuorination of the benzimidazole group but
found only marginal (<2-fold) gains in aﬃnity and potency
(see 30−32). The most potent RNase inhibitor 31 from this
scaﬀold showed moderate solubility (KSol = 38 μM), reﬂecting
the high lipophilicity (LogD7.4 = 3.7).
Cellular inhibition of IRE1α RNase function was measured
for selected compounds using a bioluminescent reporter assay
in HEK293 cells stably expressing an XBP1 luciferase fusion
mRNA to quantify XBP1 mRNA splicing (Table 3). In the
absence of ER stress, translation of the XBP1u mRNA
terminates before the luciferase sequence, while exogenous
induction of ER stress leads to IRE1α-dependent XBP1 mRNA
splicing and results in tandem translation of the XBP1s-
luciferase reporter protein. The imidazo[1,2-b]pyridazine 2
moderately inhibited tunicamycin-induced mRNA splicing.
Enhancement of the in vitro potency and aqueous solubility of
the scaﬀold, to give 22 and 26, was accompanied by increased
Table 1. In Vitro Binding and Inhibition of IRE1α Kinase
and RNase Activities by 2, 5−12
no.
IRE1α S724
autophosphorylation IC50
(μM)a
IRE1α ATP-site
binding IC50 (μM)
b
IRE1α RNase
activity IC50
(μM)c
16 0.218 (±0.15)6 1.18 (±0.17) activator
EC50 0.143
6
2 0.303 (±0.15) 1.60 (±0.91) 8.90 (±0.21)
5 >10 >10 n.d.d
6 >10 >10 n.d.
7 4.06 (±0.74) >10 >10
8 0.89 (±0.14) 46% @10 μMe >10
9 0.81 (±0.4) 0.84 (±0.42) 2.67 (±1.89)
10 >10 >10 n.d.
11 >10 >10 n.d.
12 2.7 (±1.1) >10 n.d.
aInhibition of recombinant G547 IRE1α kinase-endoribonuclease
extended (KEN) domain pS274 autophosphorylation measured in
dissociation-enhanced lanthanide ﬂuorescence immunoassay (DEL-
FIA) format, mean (±standard deviation (SD)) for n ≥ 3. bInhibition
of ATP-site LanthaScreen tracer binding to recombinant dephos-
phorylated G547 IRE1α KEN domain, mean (±SD) for n ≥ 3.
cInhibition of G547 IRE1α-dependent cleavage of a ﬂuorescence
resonance energy transfer (FRET)-labeled stem-loop RNA containing
the XBP1 cleavage site, mean (±SD) for n ≥ 3. dn.d. = not
determined. e±4%, n = 4.
Table 2. In Vitro Binding and Inhibition of IRE1α Kinase
and RNase Activities by 19−32 and Published Compound
KIRA3
no.
IRE1α S724
autophosphorylation
IC50 (μM)
a
IRE1α ATP-site
binding IC50
(μM)b
IRE1α RNase
activity IC50
(μM)c
19 0.19 (±0.11) 0.25 (±0.07) 0.48 (±0.19)
20 0.77 (±0.13)d 0.83 (±0.19) 0.13e
21 0.47 (±0.09) 0.87 (±0.24) 0.16e
22 0.32 (±0.09) 0.11 (±0.04) 0.072 (±0.011)
23 >10 >10 n.d.f
24 0.15 (±0.05) 0.14 (±0.02) 0.033e
25 0.19 (±0.01)d 0.11 (±0.01) 0.122 (±0.026)
26 0.24 (±0.09) 0.087 (±0.022) 0.027 (±0.007)
27 0.20 (±0.05) 2.0 (±0.94) 0.51e
28 0.13 (±0.06) 0.67 (±0.23) 0.18e
29 0.13 (±0.03) 0.39 (±0.11) 0.09 (±0.05)
30 0.15 (±0.02) 0.33 (±0.04) 0.10 (±0.05)
31 0.16 (±0.06) 0.27 (±0.17) 0.08 (±0.05)
32 0.16 (±0.05) 0.48 (±0.05) 0.17 (±0.09)
KIRA3 0.29 (±0.06) 0.40 (±0.16) 0.45 (±0.10)
aInhibition of recombinant G547 IRE1α KEN domain pS274
autophosphorylation measured in DELFIA format, mean (±SD) for
n ≥ 3. bInhibition of ATP-site LanthaScreen tracer binding to
recombinant dephosphorylated G547 IRE1α KEN, mean (±SD) for n
≥ 3. cInhibition of G547 IRE1α-dependent cleavage of a FRET-
labeled stem-loop RNA containing the XBP1 cleavage site, mean
(±SD) for n ≥ 3. dn = 2. eSingle determination. fn.d. = not
determined.
Table 3. Cellular Activities of Selected IRE1α Inhibitors
no.
XBP1 luciferase fusion mRNA
splicing in HEK293 cells IC50
(μM)a
cytotoxicity in HEK293
reporter cells EC50 (μM)
b
2 4.2 (±1.7) >49
22 2.9 (±0.87) 28 (±6.9)
26 1.12 (±0.24) >49
29 0.89 (±0.1) 12c
31 0.71 (±0.33) 9.0 (±1.6)
KIRA3 0.76c >49
aInhibition of tunicamycin-induced IRE1α-dependent splicing of an
XBP1u-luciferase mRNA reporter stably expressed in HEK293 cells,
mean (±SD) for n ≥ 2. bCytotoxicity in HEK293 cells stably
expressing an XBP1u-luciferase mRNA reporter, measured using the
Alamar Blue format, mean (±SD) for n ≥ 2. cSingle determination.
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cellular activity. Likewise, the most potent and soluble 3-(2-
(N-phenyl)aminobenzimidazol-5-yl) substituted analogues 29
and 31 gave submicromolar inhibitors of IRE1α activity in
cells. The optimization of in vitro potency in this series
involved addition of basic groups, which may have impaired
cell permeability and countered gains in potency for some of
the more basic molecules. The cytotoxicity of compounds in
the cell line was monitored to preclude interference in the
assay, and no compound showed high cytotoxicity in the
HEK293 cell line over the duration of the assay.
Compounds 2, 26, and 31 were proﬁled for broad kinase
selectivity, as determined by inhibition of probe binding to
recombinant human protein and lipid kinase domains at a
concentration of 1 μM (KINOMEscan, Euroﬁns; Figure 2 and
Table S1). Compound 2 gave >70% inhibition of 26/455 wild-
type and mutant kinases tested. A distinct selectivity pattern
was seen, with speciﬁc CMGC (CLK1, CLK2, CLK4,
DYRK1A, DYRK1B, HIPK4) and TK (FLT3 wild type and
mutants, KIT wild type and mutants, PDGFRB) subfamily
members showing particularly high inhibition (>90%). The
more potent derivative 26 maintained a very similar selectivity
pattern, with additional kinases in the CMGC (DYRK2,
HIPK1, HIPK2, HIPK3) and TK (PDGFRA) subfamilies
related to those inhibited by 2 showing potent (>90%)
inhibition. Overall, 54/455 wild-type and mutant kinases
tested showed >70% inhibition, consistent with the increased
potency of 26 . In contrast , the 2-(N -pheny l)-
aminobenzimidazole 31 had a diﬀerent selectivity pattern
and very high selectivity with >70% inhibition of only 4/455
kinases. While two of the CMGC kinases inhibited by 2 and 26
(CLK1 and CLK4) were inhibited to a lesser extent by 31, the
most potently inhibited kinase was another CGMC family
member PCTK2 (97% inhibition at 1 μM test concentration).
Interaction with wild-type and mutant TK subfamily kinases
was minimal for 31. The inhibitors 26 and 31 were,
respectively, 9- and 100-fold selective for IRE1α over the
IRE1β isoform, which has 80% sequence identity in the kinase
domain,34 in parallel LanthaScreen binding assays (Figure S3).
To better understand the origins of the potency and high
selectivity of the inhibitors, we determined the X-ray structure
of 2 bound to the cytosolic kinase-endoribonuclease (KEN)
domain of IRE1α (PDB 6HX1; Figure 3A,B). The complex 2-
IRE1α crystallized as a monomer in the unit cell. The kinase
domain adopted an unusual conformation in which the αC-
helix was remarkably disordered such that electron density was
not modeled for most of this important secondary structural
component. The DFG motif occupied an intermediate position
between the canonical DFG-in and DFG-out conformations,
which we term “DFG-up” for convenience. Thus, F712 was
displaced from the “in” position that characterizes the active
conformation of the regulatory hydrophobic spine of the
kinase. A related intermediate conformation of the DFG motif
has been observed in complexes of ligands bound to mutated
Aurora A kinases.35,36 In the current structure, the residue
Y628, also part of the hydrophobic spine in IRE1α, was
directed down toward the DFG motif, forming hydrogen
bonds to D711 (2.7 Å) and the bound ligand. This contrasted
with the upward orientation of Y628 seen when the regulatory
spine is intact and the IRE1α kinase domain is in the active
conformation.6 The DFG-up, Y628-down conformation of 2-
IRE1α was accompanied by an unusual folding of the
activation loop in an antiparallel double β-strand across the
face of the ATP site, forming a region of β-sheet with the P-
loop that enclosed the bound ligand. The residue H723 in the
Figure 2. Binding proﬁles of compounds 2, 26, and 31 tested at 1 μM concentrations of inhibitors against 455 wild-type and mutant human protein
and lipid kinases (KINOMEscan, Euroﬁns) (see Table S1). Kinases where probe binding was inhibited by >90% at 1 μM test compound
concentration are listed.
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Figure 3. Characterization of IRE1α inhibitor binding modes. (A) Part of the crystal structure (PDB 6HX1) of 2 (green sticks) bound to IRE1α
KEN domain (gray image) showing the conformations of the DFG motif (cyan), activation loop segment (pale cyan), Y628 (blue), K599 (gray),
and the observed part of the αC-helix (red). (B) Binding of 2 (green sticks) in the IRE1α ATP site (gray sticks) with key residues labeled.
Hydrogen bonds are shown as black dotted lines and selected water molecules as red spheres. (C) Details of the interactions of 2 (green sticks)
with the DFG motif and Y628 in the IRE1 ATP site (gray image) with key residues labeled. Hydrogen bonds are shown as black dotted lines and
selected water molecules as red spheres. (D) Comparison of 2 (purple), 1 (blue; PDB 4Z7H), Compound 16 (light blue; PDB 4U6R), and
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activation loop appeared to anchor this folding, with direct
hydrogen bonding to E651 (2.8 Å) in the kinase domain C-
terminus and a water-mediated hydrogen bond observed
between H723 and L577 in the P-loop. Folding of the
activation loop across the active site is an autoinhibitory
mechanism for some kinases. For example, structures of
imidazo[1,2-b]pyridazines and other ligands bound to the
kinase MPS1 show a single strand of the activation loop folded
across the active site parallel to the P-loop, potentially blocking
the interaction with substrate peptides.29 However, in these
cases, the kinase adopts a DFG-in conformation on ligand
binding and the αC-helix is preserved.
Within the unusual kinase ATP-site conformation, the ligand
2 bound at the hinge region, with the imidazo[1,2-b]pyridazine
ring sandwiched between L714 in the activation loop and
V586 in the β2-strand, C-terminal to the P-loop (Figure 3B).
Canonical hydrogen bonds were made from the imidazo[1,2-
b]pyridazine N1 and 8-NH to the C645 NH (3.1 Å) and C
O (3.0 Å) functionalities, respectively. This closely resembled
the binding modes described for 8-amino-imidazo[1,2-b]-
pyridazines in other kinases.28,29,37,38 An additional hydrogen
bond (2.8 Å) was observed between the indazole NH and
Y628, presumably contributing to stabilizing the tyrosine
“down” conformation. The indazole occupied a hydrophobic
pocket formed by the gatekeeper residue I642, F712 of the
DFG motif, F725 from the activation loop, and the catalytic
lysine K599. The 6-chloro substituent of 2 packed closely
against the β-sheet surface formed by L577 and G578 of the P-
loop and H723 and S724 of the activation loop. The
cyclopropylmethyl side chain of 2 reached the edge of the
ATP site and was oriented to provide a vector out into solvent.
The unusual binding mode seen for 2-IRE1α was
independently reproduced with a close analogue, 33 (PDB
6HV0), in which the cyclopropylmethyl group was replaced by
an isopropyl chain (Figure S4), supporting the likely biological
relevance of the structure. Furthermore, the observed binding
mode was consistent with the structure−activity relationships
described above for the indazole-substituted 8-amino-imidazo-
[1,2-b]pyridazines, speciﬁcally the requirement for a hydrogen
bond donor corresponding to the indazole N(1)−H (Table 1)
and the tolerance of a wide range of substitution of the 8-
amino group on the imidazo[1,2-b]pyridazine core (Table 2).
Modeling of the more potent compound 26 into the
conformation of IRE1α observed in the crystal structures
reproduced this binding mode, with the suggestion of an
additional hydrogen bond from the cyclohexylamine to E651
on the surface of the protein (Figure S5).
The unusual DFG-up inactive conformation of the kinase
domain of 2- and 33-IRE1α diﬀered considerably from other
active and inactive kinase conformations reported for ligand-
bound structures of IRE1α (Figure 3C,D).4,6,22,23 We
previously described the IRE1α kinase inhibitor-RNase
activator 1 that stabilized a classical DFG-in, active
conformation of the kinase with the activation loop extended
away from the active site, mimicking IRE1α autophosphor-
ylation and activating the RNase function through competent
dimerization of the endonuclease domain.6 In contrast, a large
sulfonamide inhibitor (named compound 16), although it also
bound to a DFG-in conformation of the kinase, was found to
cause a shift of the αC-helix that was incompatible with the
formation of the RNase domain dimer.23 A type III inhibitor of
IRE1α, GSK2850163, has been described that occupied a
pocket adjacent to the hinge region of the kinase and
promoted a DFG-out kinase conformation, with the activation
loop directed across the active site and the αC-helix further
shifted and rotated away from the active conformation.22 In
the latter two cases, although the active kinase conformation
was disrupted, the αC-helix remained intact. For 2 and 33, our
data showed a striking disruption of the αC-helix, as well as a
distinctive refolding of the activation loop around the bound
inhibitor. This conformation is incompatible with the back-to-
back dimerization required to form an active endoribonuclease
domain dimer (Figure 3E). The dimerization interface in the
kinase domain is formed by the loops β(−1)−β(0) and
β(2)−β(3) from each monomer.6 Compared to the active
IRE1α dimer structure represented by 1-IRE1α, the binding of
2 and 33 shifted the position of the kinase domain relative to
the endonuclease domain such that dimerization at the kinase
domain would lead to steric clashes of the endoribonuclease
domains.
We were unable to obtain a crystal structure of a 2-
aminobenzimidazole-substituted analogue bound to IRE1α.
Modeling of 9, the closest analogue to 2, into the structure of
2-IRE1 showed that alignment of the imidazo[1,2-b]pyridazine
cores of the two inhibitors resulted in a clash between the 2-
aminobenzimidazole substituent and residue Y628. When
Y628 was allowed to move from the “down” orientation
observed in 2-IRE1 to the “up” conformation observed in
other IRE1α structures, this minimal change resulted in a
satisfactory binding mode for the prototypical 2-(N-phenyl)-
aminobenzimidazole 9 (Figure 3F). The model retained
binding of the imidazo[1,2-b]pyridazine at the hinge region
and proposed a 180° rotation of the 2-aminobenzimidazole
relative to the indazole substituent of 2 such that a new
hydrogen bond was formed between the 2-amino group and
D711 of the DFG motif. The terminal phenyl group occupied
the space vacated by Y628 and packed against this residue now
in its upward conformation. The introduction of a hydrogen
bond to the DFG motif was consistent with precedent for
other 2-aminobenzimidazole kinase inhibitors, where this
functionality is often an isostere for urea-based inhibitors
that bind to DFG-out conformations, as we had originally
Figure 3. continued
GSK2850163 (red; PDB 4YZ9) binding to IRE1α KEN domain. Structures are overlaid on the hinge region (E643-L644-C645; lines), and the αC-
helix (L602-S619; cartoon) is shown in the three structures in which it is present. (E) Schematic overlay showing the relationship between the
DFG-out, DFG-up, and DFG-in conformations and the corresponding orientations of the observed activation loop segments (L714-S729) for
GSK2850163-IRE1α (red), 2-IRE1 (purple), compound 16-IRE1α (light blue), and 1-IRE1α (blue). (F) Comparison of components of the N-
terminal kinase domain dimerization interface for the DFG-in, active conformation of 1-IRE1α (blue and blue-white protomers) and DFG-up, and
inactive conformation of 2-IRE1α (purple). Structures are aligned on the kinase C-lobe (shown) and endonuclease C-terminal domain (not
shown). Bound ligands are rendered as sticks; (G) model of 9 (green sticks) bound to IRE1 (gray image) based on the conformation observed for
2-IRE1. Predicted hydrogen bonds are shown as black dotted lines. (H) Detail showing the movement of Y628 as positioned in 2-IRE1 (gray
image) required to accommodate the modeled binding of 9 (green sticks).
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speculated in developing the series. Moreover, the modeled
hydrogen bond to D711 was consistent with the observed
structure−activity relationships, where methylation of the 2-
amino group or imidazole nitrogens reduced activity (Table 1).
The combination of multiple kinase conformational disrup-
tions accompanying binding of the indazole and amino-
benzimidazole scaﬀolds can account for the high IRE1α kinase
selectivity of 26 and 31 (Figure 2). For 26, a discrete set of
kinases in the CAMK and TK subfamilies were also inhibited.
For this ligand, we cannot exclude the possibility that an
alternative binding mode where the indazole contributes the
donor−acceptor hinge-binding motif may be accessible in
some kinases.39,40 Interestingly, while the majority of residues
forming the binding site of 2 and 33 to IRE1α are identical in
the sequence of the isoform IRE1β, the histidine H723 in
IRE1α is replaced by a cysteine residue (C671) in IREβ
(Figure S3B).34 Since hydrogen bonding of the imidazole side
chain of H723 to E651 appeared important for the unusual
activation loop fold in the structures 2 and 33 bound to IRE1α,
we speculate that the absence of this residue may in part be
involved in the observed selectivity of the compounds for
IRE1α over IRE1β. The other major local diﬀerence (A646 in
the hinge corresponds to R594 in IRE1β34) involves a side
chain directed away from the binding site.
Figure 4. Compounds 26 and 31 inhibit IRE1α oligomerization, IRE1α autophosphorylation, IRE1α RNase activity, XBP1s protein expression,
and XBP1-dependent transcription in human cells. (A) Inhibition of tunicamycin-induced IRE1α oligomerization, measured by ﬂuorescent foci
formation in HEK293 cells stably transfected with doxycycline-inducible GFP-IRE1α after 5 h treatment with inhibitors (0−10 μM) in the absence
or presence of tunicamycin (quantiﬁcation of image ﬁelds from n = 2 experiments plotted separately). Dox = doxycycline, T = tunicamycin (10 μg/
mL). (B) Inhibition of tunicamycin-induced pS724 IRE1α autophosphorylation as measured by capillary electrophoresis immunoassay (simple
Western) relative to total IRE1α. Data shown for a single experiment representative of n = 3. (C) Inhibition of tunicamycin-induced XBP1s protein
expression in H929 cells as measured by immunoﬂuorescent assay (quantiﬁcation of image ﬁelds from n > 3 experiments). (D) Inhibition of
tunicamycin-induced XBP1s-dependent transcription of DNAJB9 mRNA as measured by real-time quantitative polymerase chain reaction (RT-
qPCR). Data shown for a single experiment representative of n = 3. Tm = tunicamycin.
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To conﬁrm the functional consequences of the unusual
binding modes of the inhibitors, we investigated the eﬀects of
26 and 31 on ER stress-induced IRE1α signaling outputs in
human cells. The eﬀects of the compounds on IRE1α
oligomerization were determined in HEK293 cells expressing
doxycycline-inducible green ﬂuorescent protein (GFP)-labeled
IRE1α that forms quantiﬁable ﬂuorescent foci in the ER
membrane under stress conditions41 (Figure 4A). GFP-IRE1α
foci produced upon treatment with tunicamycin were dose-
dependently reduced by 26 (IC50 = 1.88 ± 0.09 μM) and 31
(IC50 = 0.74 ± 0.03 μM), indicating inhibition of IRE1α
oligomer formation. No stimulation of GFP-IRE1α foci
formation was observed for either compound on its own.
Thus, the compounds are full inhibitors of oligomerization in
cells and do not show partial activation of IRE1α through
occupation of the nucleotide-binding site.
Compounds 26 and 31 inhibited both tunicamycin- and
thapsigargin-induced IRE1α-dependent splicing of XBP1
luciferase fusion mRNA in HEK293 cells (Table 3 and Figure
S6) with equivalent potencies (IC50 0.68−1.63 μM). In
parallel, inhibition of tunicamycin-induced production of
endogenous XBP1s mRNA was demonstrated in H929
myeloma cells using RT-qPCR at similar concentrations
(Figure S7). The expression of the spliced transcription factor
XBP1s following ER stress was measured by immunoﬂuor-
escent staining in H929 myeloma cells (Figure 4C).
Tunicamycin-induced expression of XBP1s protein was
inhibited by 26 and 31 with similar potencies to the inhibition
of IRE1α oligomerization and RNase activities in cells. The
expected downstream eﬀect on XBP1s-dependent transcription
in H929 cells was conﬁrmed by monitoring production of the
mRNA coding for DNAJB9, an ER-resident molecular
chaperone regulated by XBP1s8 (Figure 4D). Inhibition of
IRE1α autophosphorylation in H929 cells was also observed
on treatment with 26 and 31 (Figures 4B and S8), although
full blockade appeared to require higher concentrations than
the oligomerization and RNase functions. This is consistent
with the proposed model for IRE1α activation, where
conformationally productive oligomerization is the critical
step in activating the endoribonuclease,4 while autophosphor-
ylation contributes to stabilizing the active oligomers6 and
XBP1-independent signaling to JNK through the binding of
TRAF2.10 Previous studies by our group6 and others4 indicate
that the trans-autophosphorylation of IRE1α proceeds through
a face-to-face encounter of IRE1α protomers distinct from the
back-to-back arrangement essential for activation of the RNase
function.
■ DISCUSSION AND CONCLUSIONS
Through screening analogues of a type I IRE1α kinase
inhibitor that activates the RNase function through binding to
a classical DFG-in kinase conformation, we unexpectedly
discovered a closely related series of imidazo[1,2-b]pyridazin-
8-amine kinase inhibitors that also inhibited the RNase. This
surprising ﬁnding challenged our initial assumption that type II
or type III kinase inhibitors binding to a DFG-out
conformation of the kinase would be needed to prevent
IRE1α dimerization and activation of the RNase.
We increased the potency of the imidazo[1,2-b]pyridazin-8-
amines using design hypotheses that assumed a type I binding
mode of the core scaﬀold, leading to a series of indazoles, while
further substitution generated 2-phenyl-benzimidazoles de-
signed as potential type II inhibitors. However, crystal
structures of the indazoles 2 and 33 bound to IRE1α showed
the protein to adopt a highly unusual conformation, with the
DFG motif in an intermediate “up” position and substantial
disordering of the αC-helix. These structures and models
derived from them accounted for the structure−activity
relationships of the inhibitors, showing how a type I scaﬀold
could promote a previously unreported conformation of the
kinase domain that is incompatible with RNase domain back-
to-back dimerization required for activation of the RNase
function. The binding mode emphasized the role of the
hydrophobic spine residue Y628 of IRE1α in compound
binding and kinase conformational control.6,42
Other kinase signaling pathways have been observed to be
modulated through transactivation of dimers controlled
allosterically by kinase site occupation.43 Notably, ligand-
promoted heterodimerization of inhibitor-bound BRAF with
CRAF results in paradoxical activation of RAF signaling by
some BRAF inhibitors.44,45 Kinase site inhibitors that can
simultaneously suppress the catalytic function of kinase
monomers and their dimerization with uninhibited partners
are therefore a potentially useful therapeutic modality.46
Certain pseudokinases that lack intrinsic enzyme function
also exploit dimerization to regulate signaling pathways and
may be amenable to pharmacological intervention through
nucleotide-binding-site ligands that prevent dimerization.47
The most advanced compound we studied showed nano-
molar potency for biochemical inhibition of the kinase and
RNase and, importantly, was highly selective for IRE1α over
other kinases. It is possible that the high selectivity of 31
reﬂects binding to the unusual IRE1α kinase conformation
incorporating multiple disruptions, as modeled for the
analogue 9. Although elements of the conformational
disruption of the IRE1α kinase domain have been seen
separately in other contexts,22,23,28,29,35,36 to our knowledge,
they have not been observed occurring simultaneously. Our
ﬁndings thus increase the repertoire of conformations
discovered for IRE1α and provide a means to achieve high
speciﬁcity for IRE1α inhibition over other kinases, with reliable
translation of kinase ATP-site occupation into RNase
inhibition.
We conﬁrmed that compounds engaging the newly
discovered IRE1α conformation resulted in the inhibition of
ER stress-induced signaling through IRE1α in multiple human
cell types, resulting in inhibition of XBP1-dependent tran-
scription. We determined substantial inhibition of the IRE1α
signaling pathways to occur in cells at concentrations of 26 and
31 between ca. 1 and 2 μM in short-term assays. Selective
IRE1α kinase-endoribonuclease inhibitors may have utility in
situations where direct cytotoxicity is not the desired outcome
of IRE1α-XBP1s inhibition, such as the modulation of XBP1s-
dependent suppression of dendritic immune cell function. The
identiﬁcation of compounds 26 and 31 and their binding mode
demonstrates a new means to achieve highly selective
inhibition of IRE1α, which may be important in such contexts
where the biology of untransformed host cells is targeted.48
■ EXPERIMENTAL SECTION
IRE1α Autophosphorylation Assay. Inhibition of IRE1α
autophosphorylation was measured using a dissociation-enhanced
lanthanide ﬂuorescence immunoassay (DELFIA) as described
previously.31 Brieﬂy, dephosphorylated IRE1α G547-L977 (700
nM) was incubated for 25 min with 100 μM ATP in 15 μL of
assay buﬀer (40 mM Tris (pH 7.5), 20 mM MgCl2, and 1 mM 1,4-
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dithiothreitol (DTT)). The assay was stopped by the addition of 40
mM ethylenediaminetetraacetic acid. Samples were transferred to a
384-well high-binding plate and incubated overnight at 4 °C. The
plates were washed three times in 0.1% Tween-20, followed by
blocking in 5% nonfat skimmed milk in phosphate-buﬀered saline
(PBS) for 30 min at 37 °C. The plates were washed again before
application of α-pS724 phospho-speciﬁc IRE1α primary antibody31
(160 pg/mL) in PBS to each well and incubated for 1.5 h at 37 °C.
The plates were washed before addition of a europium-labeled α-
rabbit secondary antibody (PerkinElmer Life Sciences). Another wash
step was followed by the addition of DELFIA enhancement solution
(PerkinElmer Life Sciences). Assay plates were read on an EnVision
multimode plate reader (PerkinElmer Life Sciences).
IRE1α RNase Assay. Inhibition of IRE1α endoribonuclease
activity was measured using a FRET de-repression assay monitoring
cleavage of a 29-nucleotide stem-loop RNA containing the XBP1
cleavage site sequence and labeled with a ﬂuorescence emitter
(ﬂuorescein amidite (FAM)) and a ﬂuorescence quencher (Black
Hole Quencher (BHQ)) at the 5′ and 3′ ends, respectively (Figure
S2), as described previously.30,31 Brieﬂy, varying volumes of
compound in DMSO or DMSO alone were added to a low-volume
384-well plate (3676, Corning) to give ﬁnal concentrations ranging
from 100 μM to 0.313 nM using an Echo acoustic liquid dispenser
(Labcyte, CA). Nonphosphorylated IRE1α G547-L977 was added to
a ﬁnal concentration of 200 nM. After incubating for 30 min at 30 °C,
hairpin RNA XBP1 substrate mimic labeled with ﬂuorescein and
Black Hole Quencher (5′ FAM-GAACAAGAUAUCCGCA-
GCAUAUACAGUUC-3′ BHQ, Euroﬁns MWG Operon, Germany)
was added to 100 nM ﬁnal concentration. After incubation for a
further 15 min at 30 °C, the ﬂuorescein ﬂuorescence was measured on
an EnVision multimode plate reader (PerkinElmer Life Sciences).
Fluorescence in the presence of compound was expressed relative to
that of DMSO alone (no compound).
IRE1α ATP-Site Binding Assay. Compound binding to IRE1α
was measured using a LanthaScreen Eu Kinase binding FRET assay
monitoring the displacement of an ATP-site tracer by inhibitors.
Brieﬂy, a master mix of (7.5 μL) 50 nM dephosphorylated IRE1α
G547-L977, 2 nM biotinylated anti-his-tag antibody (PV6089,
Thermo Fisher Scientiﬁc), 2 nM streptavidin−europium (PV5899,
Thermo Fisher Scientiﬁc) diluted in assay buﬀer (PV3189, Thermo
Fisher Scientiﬁc), and 1 mM 1,4-dithiothreitol (DTT) (D0632,
Sigma-Aldrich) was incubated with 7.5 μL of 75 nM tracer (Tracer
236, Thermo Fisher Scientiﬁc) in assay buﬀer for 60 min at rt. During
the incubation, the 384-well white low-volume plate (3674, Corning)
was covered with foil. Assay plates were read on an EnVision
multimode plate reader (PerkinElmer Life Sciences).
X-ray Crystallography of 2-IRE1α (PDB 6HX1). Determination
of the structure of 2-IRE1α was conducted by Proteros Biostructures
GmbH (Martinsried, Germany). Expression, puriﬁcation, and
crystallization of IRE1α with compound were performed by analogy
to previously reported protocols.6 Crystals were ﬂash-frozen and data
were collected at 100 K at the Swiss Light Source (PXI/X06SA,
PILATUS 6 M detector; SLS, Villigen, Switzerland) using cryogenic
conditions. Data were processed using the programs XDS and
XSCALE.49 The structure of apo-IRE1α was solved by molecular
replacement using a previously solved structure of IRE1α as a search
model. Subsequent model building and reﬁnement was performed
according to standard protocols with the software packages CCP450
and COOT.51 For the calculation of the free R-factor, 5.4% of
measured reﬂections were excluded from the reﬁnement procedure
(see Table S2). The ligand parameterization and generation of the
corresponding library ﬁles were carried out with CORINA (Molecular
Networks, GmbH). The water model was built with the “Find waters”
algorithm of COOT by placing water molecules in peaks of the Fo−
Fc map contoured at 3.0, followed by reﬁnement with REFMAC552
and checking all waters with the validation tool of COOT. The
criteria for the list of suspicious waters were: B-factor greater than 80
Å2, 2Fo−Fc map less than 1.2σ, and distance to the closest contact
less than 2.3 Å or more than 3.5 Å. The suspicious water molecules
and those in the ligand binding site (distance to ligand less than 10 Å)
were checked manually. The occupancy of side chains in negative
peaks in the Fo−Fc map (contoured at −3.0σ) was set to zero and
subsequently to 0.5 if a positive peak occurred after the next
reﬁnement cycle.
In Silico Chemistry. The enzyme−inhibitor crystal structure of 2-
IRE1α (PDB 6HX1) was prepared for modeling using Protein
Preparation Wizard in Maestro,53 and all water molecules, apart from
that interacting with residues L577 and H723, were removed. To
propose predicted binding modes of the inhibitors, Glide (grid-based
ligand docking with energetics)54 was used for the docking
experiments. The receptor grid (model A; for 26 bound to IRE1α)
was deﬁned by a grid box of 25 × 25 × 25 Å3 with a default inner box
(10 × 10 × 10 Å3) centered on the ligand 2 in 6HX1. For the “Y628-
up” conformation (model B; for 9 bound to IRE1α), the side-chain
orientation of residue Tyr628 in 6HX1 was ﬂipped from the observed
rotamer to the most probable rotamer without steric clashes according
to the Schrödinger in-built rotamer library, energy-minimized, and a
Glide receptor grid subsequently prepared as described above.
Ligands were prepared using LigPrep55 applying the OPLS_2005
force ﬁeld with possible tautomeric and ionization states in the pH
range 5.0−9.0 generated. Using Glide Extra Precision (XP) settings,
ﬂexible docking of ligands was conducted with the minimal
constraints deﬁned as satisfying at least one H-bonding interaction
with either residue R643 or C645 (kinase hinge region interactions),
analogous to the interactions observed in the structure of 2-IRE1α.
Model A was used for the binding mode predictions of 26, whereas
model B was applied to predict the binding mode of 9.
Hit compound 2 was analyzed for potential pan-assay interference
behaviors using open access in silico tools (http://zinc15.docking.
org/patterns/home), and no substructural alerts were returned.
Speciﬁc inhibition of IRE1α kinase was demonstrated in two
independent assay formats for 2 and active analogues (Tables 1 and
2).
General Synthetic Chemistry. Reactions were carried out under
N2. Organic solutions were dried over MgSO4 or Na2SO4. Starting
materials and solvents were purchased from commercial suppliers and
were used without further puriﬁcation. Reactions heated by
microwave irradiation were carried out using a Biotage Initiator
microwave reactor. Reactions in sealed tubes were carried out in
pressure vessels with shield protection. Ion-exchange chromatography
was performed using ISOLUTE Flash SCX-II (acidic) or Flash NH2
(basic) resin cartridges. Silica column chromatography was performed
using Biotage SP1 or Isolera medium-pressure chromatography
systems, using prepacked silica gel cartridges (normal phase, Biotage
SNAP KP-Si; reverse phase, Biotage SNAP Ultra C18). Preparative
high-performance liquid chromatography (HPLC) was carried out at
rt using a 1200 Series Preparative HPLC (Agilent, Santa Clara) over a
15 min gradient elution from 60:40 to 0:100 water/MeOH (both
modiﬁed with 0.1% formic acid) at ﬂow rates of 5, 20, or 40 mL/min
depending on the column size used. Standard injections of 500 μL to
2 mL (with needle wash) of the sample were made onto ACE 5 C18-
PFP columns (5 μm, 250 × 10/250 × 21.2/250 × 30 mm2, Advanced
Chromatography Technologies, Aberdeen, U.K.). UV−vis spectra
were acquired at 254 nm on a 1200 Series Prep Scale diode array
detector (Agilent, Santa Clara). NMR spectra were recorded on
Bruker AMX500 or AV600 instruments using internal deuterium
locks. Chemical shifts (δ) are reported relative to tetramethylsilane (δ
= 0) and/or referenced to the solvent in which they were measured.
Compounds were assessed for purity by tandem HPLC−MS.
Combined HPLC−MS analyses were recorded using an Agilent
6210 time-of-ﬂight (ToF) HPLC−MS with a Merck Purospher STAR
column (RP-18e, 30 × 4 mm2) or a Waters Xevo G2QToF HPLC−
MS with a Phenomenex Kinetex C18 column (30 × 2.1 mm2, 2.6 μm,
100 A). Analytical separation was carried out at 40 °C with UV
detection at 254 nm, and ionization was by positive-ion electrospray.
The mobile phase was a mixture of MeOH (solvent A) and water
(solvent B), both containing formic acid at 0.1%. Gradient elution
from 10:90 (A/B) to 90:10 (A/B) was carried out over 2 min (ﬂow
rate: Agilent, 3 mL/min; Xevo, 0.5 mL/min) or 4 min (ﬂow rate:
Agilent, 1.5 mL/min; Xevo, 0.3 mL/min). Biologically evaluated
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compounds gave >95% purity as determined by these methods (Table
S2).
6-Chloro-N-(cyclopropylmethyl)-3-(1H-indazol-5-yl)imidazo[1,2-
b]pyridazin-8-amine (2). 4-Bromo-6-chloropyridazin-3-amine (10.0
g, 48.1 mmol) and 2-chloroacetaldehyde (31.8 mL, 250 mmol; 50%
w/w aqueous solution) in EtOH (67 mL) were stirred at 50 °C for 22
h. The mixture was cooled to rt, concentrated, and partitioned
between CH2Cl2 (300 mL) and saturated aqueous NaHCO3 (200
mL). The aqueous phase was extracted with CH2Cl2 (150 mL). The
combined organic layers were dried, ﬁltered, and evaporated to
dryness to give 8-bromo-6-chloroimidazo[1,2-b]pyridazine (11.2 g,
quantitative) that was taken to the next step without further
puriﬁcation. 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 1.2 Hz,
1H), 7.84 (d, J = 1.1 Hz, 1H), 7.40 (s, 1H); 13C NMR (126 MHz,
CDCl3) δ 145.9, 137.0, 134.8, 124.2, 121.2, 118.8; liquid
chromatography mass spectrometry (LCMS) (2 min) electrospray
ionization (ESI), (m/z) tR = 1.04 min, m/z (ESI
+) 233 (M + H+). N-
Bromosuccinimide (5.17 g, 29.0 mmol) was added to a solution of 8-
bromo-6-chloroimidazo[1,2-b]pyridazine (4.50 g, 19.4 mmol) in
CHCl3 (59 mL) at 0 °C. The mixture was warmed to rt and stirred
for 18 h. The mixture was partitioned between saturated aqueous
NaHCO3 (150 mL) and CH2Cl2 (100 mL × 2). The combined
organic layers were dried, ﬁltered, and evaporated to dryness. Silica
column chromatography, eluting with 30% EtOAc−hexanes, gave 3,8-
dibromo-6-chloroimidazo[1,2-b]pyridazine (3) (5.05 g, 84%). 1H
NMR (500 MHz, CDCl3) δ 7.85 (s, 1H), 7.46 (s, 1H);
13C NMR
(126 MHz, CDCl3) δ 147.0, 137.5, 135.3, 124.3, 121.4, 103.2; LCMS
(2.0 min) tR = 1.36 min, m/z (ESI
+) 311 (M + H+). Cyclo-
propanemethylamine (4.82 mL, 56.2 mmol) was added to a stirred
solution of 3 (3.50 g, 11.24 mmol) in THF (56 mL) at rt. After 3 h,
the mixture was evaporated and partitioned between saturated
aqueous NaHCO3 (200 mL) and CH2Cl2 (100 mL × 2). The
combined organic layers were washed with brine (100 mL), dried, and
evaporated to dryness. Silica column chromatography, eluting with
15−20% EtOAc−hexanes , gave 3 -b romo-6 -ch lo ro -N -
(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine (4) (3.20 g,
93%). 1H NMR (500 MHz, CDCl3) δ 7.49 (s, 1H), 6.04 (s, 1H),
6.00 (br t, J = 5.3 Hz, 1H), 3.17 (dd, J = 5.2, 7.1 Hz, 2H), 1.20−1.17
(m, 1H), 0.69−0.66 (m, 2H), 0.36−0.33 (m, 2H); 13C NMR (126
MHz, CDCl3) δ 149.5, 142.9, 133.1, 130.9, 101.1, 92.2, 47.8, 10.0, 3.8
(2C); LCMS (2.0 min) tR = 1.63 min, m/z (ESI
+) 303 (M + H+). N2
was bubbled for 10 min through a mixture of 4 (0.096 g, 0.318
mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole
(0.121 g, 0.350 mmol), and aq Na2CO3 (2 M; 0.637 mL, 1.27
mmol) in 1,4-dioxane (1.59 mL). Pd(OAc)2 (7.1 mg, 0.032 mmol)
and 1,1′-bis(di-tert-butylphosphino)ferrocene (0.017 g, 0.032 mmol)
were added and the mixture was heated at 135 °C in a sealed tube for
22 h. The mixture was cooled and puriﬁed by ion-exchange
chromatography on acidic resin (5 g), eluting with 2 M NH3 in
MeOH. The fractions containing product were concentrated and
puriﬁed by silica column chromatography, eluting with 5% MeOH−
CH2Cl2, to give 2 (0.047 g, 44%).
1H NMR (500 MHz, DMSO-d6) δ
13.18 (s, 1H), 8.51 (t, J = 1.1 Hz, 1H), 8.19 (t, J = 1.2 Hz, 1H), 8.07−
7.79 (m, 3H), 7.66 (dt, J = 8.9, 0.9 Hz, 1H), 6.34 (s, 1H), 3.32 (s,
2H), 1.23−1.14 (m, 1H), 0.51−0.45 (m, 2H), 0.35−0.27 (m, 2H);
13C NMR (126 MHz, DMSO-d6) δ 147.6, 143.7, 139.1, 134.2, 132.9,
129.0, 128.8, 125.5, 122.9, 120.8, 118.4, 110.4, 90.6, 46.1, 10.2, 3.4
(2C); LCMS (2 min) tR = 1.50 min, m/z (ESI
+) 339 (M + H+); high-
resolution mass spectrometry (HRMS) m/z calcd for C17H16N6
35Cl
(M + H) 339.1125, found 338.1133.
6-Chloro-N-(cyclopropylmethyl)-3-(1-methyl-1H-indazol-5-yl)-
imidazo[1,2-b]pyridazin-8-amine (5). A mixture of 1-methyl-5-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (0.086 g,
0.333 mmol), 4 (0.084 g, 0.278 mmol), aqueous Na2CO3 (2 M;
0.56 mL, 1.11 mmol), and Pd(OAc)2 (6.23 mg, 0.028 mmol), and
1,1′-bis(di-tert-butylphosphino)ferrocene (0.013 g, 0.028 mmol) in
1,4-dioxane (1.4 mL) was heated at 120 °C in a sealed tube for 22 h.
The mixture was cooled, absorbed onto silica gel, and puriﬁed by
silica column chromatography, eluting with 70% EtOAc−hexanes, to
give 5 (0.046 g, 47%). 1H NMR (500 MHz, DMSO-d6) δ 8.52 (dd, J
= 1.6, 0.8 Hz, 1H), 8.17 (d, J = 1.0 Hz, 1H), 8.02−7.93 (m, 3H), 7.76
(dt, J = 9.0, 0.9 Hz, 1H), 6.34 (s, 1H), 4.09 (s, 3H), 3.31−3.17 (m,
2H), 1.21−1.15 (m, 1H), 0.51−0.44 (m, 2H), 0.35−0.26 (m, 2H);
13C NMR (126 MHz, DMSO-d6) δ 148.1, 144.1, 139.3, 133.5, 133.4,
129.5, 129.1, 125.9, 124.0, 121.4, 118.9, 110.5, 91.1, 46.5, 35.9, 10.7,
3.9 (2C); LCMS (2 min) tR = 1.56 min, m/z (ESI
+) 353 (M + H+);
HRMS m/z calcd for C18H18N6
35Cl (M + H) 353.1281, found
353.1275.
6-Chloro-N-(cyclopropylmethyl)-3-(1H-indazol-6-yl)imidazo[1,2-
b]pyridazin-8-amine (6). N2 was bubbled for 10 min through a
mixture of 4 (0.073 g, 0.242 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indazole (0.065 g, 0.266 mmol), and aqueous
Na2CO3 (2 M; 0.48 mL, 0.968 mmol) in 1,4-dioxane (1.21 mL).
Pd(OAc)2 (5.4 mg, 0.024 mmol) and 1,1′-bis(di-tert-
butylphosphino)ferrocene (0.013 g, 0.024 mmol) were added and
the mixture was heated at 135 °C in a sealed tube for 15 h. The
mixture was cooled and puriﬁed by ion-exchange chromatography on
acidic resin (5 g), eluting with 2 M NH3 in MeOH. The fractions
containing product were concentrated and puriﬁed by silica column
chromatography, eluting with 5% MeOH−CH2Cl2, to give 6 (0.042 g,
51%). 1H NMR (500 MHz, DMSO-d6) δ 13.32−13.16 (m, 1H), 8.49
(q, J = 1.1 Hz, 1H), 8.12−8.08 (m, 2H), 8.03 (t, J = 6.1 Hz, 1H), 7.86
(dd, J = 8.5, 0.9 Hz, 1H), 7.71 (dt, J = 8.5, 1.0 Hz, 1H), 6.40 (d, J =
1.5 Hz, 1H), 3.34 (s, 2H), 1.24−1.14 (m, 1H), 0.53−0.45 (m, 2H),
0.35−0.28 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 147.7, 143.7,
140.0, 139.9, 133.5, 130.0, 128.3, 126.0, 121.9, 120.8, 119.5, 107.0,
90.9, 46.1, 10.2, 3.4 (2C); LCMS (4 min), tR = 3.21 min, m/z (ESI
+)
339 (M + H+); HRMS m/z calcd for C17H15N6
35Cl (M + H)
339.1119, found 339.1115.
6-Chloro-N-(cyclopropylmethyl)-3-(1H-indol-5-yl)imidazo[1,2-
b]pyridazin-8-amine (7). Prepared from 4 and (1H-indol-5-yl)-
boronic acid using the method described for 6 to give 7 (50%). 1H
NMR (500 MHz, DMSO-d6) δ 11.23 (s, 1H), 8.29−8.20 (m, 1H),
7.88 (t, J = 6.1 Hz, 1H), 7.84 (s, 1H), 7.68 (dd, J = 1.7, 8.5 Hz, 1H),
7.50 (dt, J = 0.9, 8.6 Hz, 1H), 7.40 (t, J = 2.8 Hz, 1H), 6.53 (ddd, J =
0.9, 1.9, 3.1 Hz, 1H), 6.30 (s, 1H), 3.25 (s, 2H), 1.19 (dd, J = 2.0, 4.9
Hz, 1H), 0.52−0.45 (m, 2H), 0.34−0.28 (m, 2H); 13C NMR (126
MHz, DMSO-d6) δ 147.4, 143.6, 135.4, 132.5, 129.9, 128.4, 127.6,
126.2, 120.5, 119.3, 118.6, 111.6, 101.6, 90.3, 46.1, 10.3, 3.4 (2C);
LCMS (2 min) tR = 1.52 min, m/z (ESI
+) 338 (M + H+); HRMS m/z
calcd for C18H16N5
35Cl (M + H) 338.1172, found 338.1161.
6-Chloro-N-(cyclopropylmethyl)-3-(1H-benzo[d]imidazol-5-yl)-
imidazo[1,2-b]pyridazin-8-amine (8). Prepared from 4 and 6-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole
using the method described for 6 with puriﬁcation by preparative
HPLC to give 8 (5%). 1H NMR (500 MHz, DMSO-d6) δ 12.60 (d, J
= 36.4 Hz, 1H), 8.39 (d, J = 8.9 Hz, 1H), 8.28 (s, 1H), 7.95 (d, J =
15.4 Hz, 2H), 7.88−7.60 (m, 2H), 6.34 (s, 1H), 3.25 (s, 2H), 1.23−
1.14 (m, 1H), 0.52−0.45 (m, 2H), 0.35−0.28 (m, 2H); 13C NMR
(126 MHz, DMSO-d6) δ 148.0, 144.1, 143.4, 133.4, 129.5 (2C),
122.7, 121.6, 91.0, 46.5, 10.7, 3.9 (2C); LCMS (2 min) tR = 1.19 min,
m/z (ESI+) 339 (M + H+); HRMS m/z calcd for C17H15N6
35Cl (M +
H) 339.1125, found 339.1127.
6-Chloro-N-(cyclopropylmethyl)-3-(2-(phenylamino)-1H-benzo-
[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (9). A mixture of
5-bromo-2-chloro-1H-benzo[d]imidazole (5.00 g, 21.6 mmol) and
aniline (10.1 mL, 110 mmol) was heated by microwave irradiation at
180 °C for 60 min. The mixture was cooled, diluted with EtOAc (60
mL), and washed with water (60 mL) and brine (60 mL). The
organic layer was dried and concentrated. Silica chromatography,
eluting with 0−2% MeOH−CH2Cl2, gave 5-bromo-N-phenyl-1H-
benzo[d]imidazol-2-amine (4.67 g, 75%). 1H NMR (500 MHz,
DMSO-d6) δ 11.02 (s, 1H), 9.54 (s, 1H), 7.76−7.69 (m, 2H), 7.46 (s,
1H), 7.35−7.27 (m, 2H), 7.24 (d, J = 8.2 Hz, 1H), 7.11 (dd, J = 2.0,
8.4 Hz, 1H), 6.98−6.91 (m, 1H); 13C NMR (126 MHz, DMSO-d6) δ
151.4, 140.5, 128.8 (2C), 122.9, 122.2, 120.9, 118.1, 117.9, 117.3
(2C), 112.1, 111.0; LCMS (2 min) tR = 0.95 min, m/z (ESI
+) 288
and 290 (M + H+); HRMS m/z calcd for C13H10N3
79Br (M + H)
288.0136, found 288.0148. DMAP (0.4 g, 3.24 mmol) and di-tert-
butyl-dicarbonate (8.84 g, 40.5 mmol) were added to a solution of 5-
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bromo-N-phenyl-1H-benzo[d]imidazol-2-amine (4.67 g, 16.2 mmol)
in dry THF (160 mL). The mixture was stirred at rt for 16 h and then
concentrated. The residue was dissolved in EtOAc (100 mL) and
washed with water (100 mL) and brine (100 mL). The organic layer
was dried and concentrated. Silica chromatography, eluting with 0−
2% MeOH-CH2Cl2 , gave t er t -buty l 5-bromo-2-(( t er t -
butoxycarbonyl)(phenyl)amino)-1H-benzo[d]imidazole-1-carboxy-
late (7.9 g, quantitative) as a mixture of three di-Boc-protected
isomers, which was used directly in the next step. LCMS (2 min) tR =
1.69, 1.87, 1.91 min; m/z (ESI+) 488 and 490 (M + H+). A portion of
the material (5.4 g, 11.1 mmol) was dissolved in dry 1,4-dioxane (110
mL) and stirred at rt. Bis(pinacolato)diboron (3.37 g, 13.3 mmol),
1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (0.81
g, 1.11 mmol), and KOAc (2.17 g, 22.1 mmol) were added and the
mixture was heated at 100 °C for 15 h. The mixture was cooled,
ﬁltered through celite, and concentrated. The residue was dissolved in
EtOAc (50 mL) and washed with water (50 mL) and brine (50 mL).
The organic layer was dried and concentrated. Silica chromatography,
eluting with 0−10% EtOAc−cyclohexane, gave tert-butyl 2-((tert-
butoxycarbonyl)(phenyl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-benzo[d]imidazole-1-carboxylate 13 (4.40 g, 74%)
as a mixture of three di-Boc protected isomers, which was used
directly in the next step. LCMS (2 min) tR = 1.70 min, 1.78 min, 1.82
min; m/z (ESI+) 536 (M + H+). The mixture of isomers of 13 was
reacted with 4 using the method described for 6 to give 9 (33%). 1H
NMR (500 MHz, DMSO-d6) δ 11.14 and 11.01 (2 × s, 1H, NH);
9.53 and 9.50 (2 × s, 1H, NH), 8.06 (dd, J = 1.7, 11.6 Hz, 1H), 7.93−
7.84 (m, 2H), 7.82−7.74 (m, 2H), 7.62 (td, J = 1.8, 7.9 Hz, 1H), 7.41
(dd, J = 8.2, 28.3 Hz, 1H), 7.33 (td, J = 2.9, 8.0 Hz, 2H), 6.94 (td, J =
1.2, 7.2 Hz, 1H), 6.31 (s, 1H), 3.25 (s, 2H), 1.23−1.15 (m, 1H),
0.53−0.45 (m, 2H), 0.35−0.29 (m, 2H); 13C NMR (126 MHz,
DMSO-d6) δ 151.4, 151.2, 147.5, 143.6, 143.2, 143.1, 140.7, 132.9,
132.7, 132.6, 129.7 (2C), 128.8, 128.5, 120.9, 120.7, 120.0, 119.9,
119.0, 117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.3, 46.1, 10.2,
3.4 (2C); LCMS (2 min) tR = 1.30 min, m/z (ESI
+) 430 (M + H+);
HRMS m/z calcd for C23H20N7
35Cl (M + H) 430.1547, found
430.1537.
6-Chloro-N-(cyclopropylmethyl)-3-(2-(methyl(phenyl)amino)-
1H-benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (10). A
mixture of 5-bromo-2-chloro-1H-benzo[d]imidazole (0.700 g, 3.02
mmol) and N-methylaniline (0.98 mL, 9.07 mmol) in EtOH (7 mL)
was heated under microwave irradiation at 180 °C for 30 min. The
mixture was cooled and concentrated. Silica chromatography, eluting
with 10% EtOAc−cyclohexane and then with 50% EtOH−EtOAc,
gave 5-bromo-N-methyl-N-phenyl-1H-benzo[d]imidazol-2-amine
(0.800 g, 88%). 1H NMR (500 MHz, DMSO-d6) δ 12.85 (br s,
1H), 7.54 (d, J = 3.1 Hz, 4H), 7.45 (d, J = 1.6 Hz, 1H), 7.41 (tt, J =
2.7, 6.0 Hz, 1H), 7.30−7.23 (m, 2H), 3.56 (s, 3H); 13C NMR (126
MHz, DMSO-d6) δ 152.1, 142.4, 130.1 (2C), 127.3, 125.4 (2C),
124.5, 114.5, 113.6, 113.3 (2 quaternary C not observed; NCH3
obscured by solvent but detected in heteronuclear single quantum
coherence NMR); LCMS (2 min) tR = 0.94 min, m/z (ESI
+) 302 and
304 (M + H+); HRMS m/z calcd for C14H12N3
79Br (M + H)
302.0293, found 302.0300. A mixture of 5-bromo-N-methyl-N-
phenyl-1H-benzo[d]imidazol-2-amine (0.800 g, 2.65 mmol), bis-
(pinacolato)diboron (0.690 g, 2 .73 mmol) , 1 ,1 ′ -b is -
(diphenylphosphino)ferrocene-palladium(II) dichloride (0.190 g,
0.260 mmol), and KOAc (0.520 g, 5.30 mmol) in dry 1,4-dioxane
(32 mL) was heated at 100 °C for 15 h. The mixture was cooled,
ﬁltered through celite, and concentrated. Ion-exchange chromatog-
raphy on acidic resin, eluting with 2 M NH3 in MeOH, gave N-
methyl-N-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
benzo[d]imidazol-2-amine (14) (0.29 g, 31%), which was used in the
next step without further puriﬁcation. LCMS (2 min) tR = 1.03 min,
m/z (ESI+) 350 (M + H+). The crude product 14 was reacted with 4
using the method described for 6 to give 10 (24%). 1H NMR (500
MHz, DMSO-d6) δ 11.45 (s, 1H), 8.01 (d, J = 1.6 Hz, 1H), 7.90 (t, J
= 6.1 Hz, 1H), 7.84 (s, 1H), 7.57 (dd, J = 1.7, 8.2 Hz, 1H), 7.49−7.42
(m, 4H), 7.32 (d, J = 8.1 Hz, 1H), 7.27−7.20 (m, 1H), 6.30 (s, 1H),
3.34 (s, 3H), 3.24 (s, 2H), 1.24−1.11 (m, 1H), 0.52−0.43 (m, 2H),
0.35−0.26 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 154.8, 147.4,
144.7, 143.6, 132.6, 129.6, 129.4 (2C), 128.4, 124.8, 123.9 (2C),
119.5, 90.3, 46.1, 38.8, 10.2, 3.4 (2C), 5 quaternary C not observed;
LCMS (2 min) tR = 1.25 min, m/z (ESI
+) 444 (M + H+); HRMS m/z
calcd for C24H22N7
35Cl (M + H) 444.1703, found 444.1703.
6-Chloro-N-(cyclopropylmethyl)-3-(1-methyl-2-(phenylamino)-
1H-benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (11).
Isothiocyanatobenzene (0.20 mL, 0.23 mmol) and EDC (0.56 g,
2.9 mmol) were added to a stirred solution of N1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (15)56 in
dry THF (16 mL) at rt. The mixture was heated to 50 °C for 16
h. The mixture was concentrated and the residue was partitioned
between water (30 mL) and EtOAc (30 mL). The organic layer was
washed with brine (30 mL), dried, and concentrated. Ion-exchange
chromatography on acidic resin, eluting with 2 M NH3−MeOH, gave
1-methyl-N-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-benzo[d]imidazol-2-amine (16) (0.25 g, 45%). 1H NMR (500
MHz, DMSO-d6) δ 8.94 (s, 1H), 7.82−7.90 (m, 2H), 7.65 (d, J = 0.9
Hz, 1H), 7.41 (dd, J = 1.1, 7.9 Hz, 1H), 7.29−7.35 (m, 3H), 6.96 (tt,
J = 1.2, 7.4 Hz, 1H), 3.72 (s, 3H), 1.30 (s, 12H); 13C NMR (126
MHz, DMSO-d6) δ 150.8, 141.4, 140.8, 136.8, 128.6 (2C), 126.3,
122.3, 121.1, 120.1, 117.9 (2C), 107.7, 83.2 (2C), 29.1, 24.7 (4C);
LCMS (2 min) tR = 1.10 min, m/z (ESI
+) 350 (M + H+); HRMS m/z
calcd for C20H25BN3O2 (M + H) 350.2043, found 350.2035. The
product 16 was combined with 4 using the method described for 6
with puriﬁcation by preparative HPLC to give 11 (15%). 1H NMR
(500 MHz, DMSO-d6) δ 8.99 (s, 1H), 8.12 (dd, J = 0.5, 1.6 Hz, 1H),
7.94−7.87 (m, 4H), 7.71 (dd, J = 1.6, 8.3 Hz, 1H), 7.42 (d, J = 8.2
Hz, 1H), 7.38−7.30 (m, 2H), 6.97 (tt, J = 1.1, 7.3 Hz, 1H), 6.32 (s,
1H), 3.76 (s, 3H), 3.25 (s, 1H), 1.29−1.13 (m, 2H), 0.52−0.43 (m,
2H), 0.35−0.28 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 151.1,
147.5, 143.7, 141.8, 140.8, 134.0, 132.7, 129.5, 128.7, 128.6 (2C),
121.3, 121.2, 118.9, 118.0 (2C), 114.3, 108.2, 90.4, 46.1, 29.2, 10.2,
3.4 (2C); LCMS (2 min) tR = 1.41 min, (ESI
+) 444 (M + H+);
HRMS m/z calcd for C24H23N7
35Cl (M + H) 444.1703, found
444.1706.
6-Chloro-N-(cyclopropylmethyl)-3-(1-methyl-2-(phenylamino)-
1H-benzo[d]imidazol-6-yl)imidazo[1,2-b]pyridazin-8-amine (12).
Isothiocyanatobenzene was combined with N1-methyl-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (17)53
using the method described for 16 to give 1-methyl-N-phenyl-6-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-
amine (18) (17%). 1H NMR (500 MHz, DMSO-d6) δ 9.00 (s, 1H),
7.81−7.93 (m, 2H), 7.56 (d, J = 1.0 Hz, 1H), 7.42 (dd, J = 1.1, 7.8
Hz, 1H), 7.28−7.38 (m, 3H), 6.97 (tt, J = 1.1, 7.3 Hz, 1H), 3.73 (s,
3H), 1.31 (s, 12H); LCMS (2 min) tR = 1.25 min, 350 (M + H
+).
The product 18 was combined with 4 using the method described for
6 to give 12 (38%). 1H NMR (500 MHz, DMSO-d6) δ 9.02 (s, 1H),
7.97 (d, J = 1.6 Hz, 1H), 7.96−7.91 (m, 2H), 7.91−7.87 (m, 2H),
7.81 (dd, J = 1.7, 8.3 Hz, 1H), 7.50−7.46 (m, 1H), 7.38−7.30 (m,
2H), 6.97 (tt, J = 1.1, 7.2 Hz, 1H), 6.32 (s, 1H), 3.77 (s, 3H), 3.25 (s,
2H), 1.26−1.13 (m, 1H), 0.52−0.45 (m, 2H), 0.35−0.28 (m, 2H);
13C NMR (126 MHz, DMSO-d6) δ 151.3, 147.5, 143.6, 141.5, 140.7,
134.4, 132.7, 129.5, 128.7, 128.6 (2C), 121.3, 120.2, 120.0, 118.1
(2C), 115.9, 106.3, 90.4, 46.1, 29.1, 10.2, 3.5 (2C); LCMS (2 min) tR
= 1.41 min, m/z (ESI+) 444 (M + H+); HRMS m/z calcd for
C24H23N7
35Cl (M + H) 444.1703, found 444.1704.
6-Chloro-3-(1H-indazol-5-yl)-N-(tetrahydro-2H-pyran-4-yl)-
imidazo[1,2-b]pyridazin-8-amine (19). A mixture of 3 (150 mg,
0.482 mmol) and tetrahydro-2H-pyran-4-amine (73 mg, 1.5 equiv,
0.723 mmol) in THF (1.2 mL) was stirred at rt for 20 h. The mixture
was diluted with THF (3 mL), and polystyrene−benzaldehyde resin
(0.50 g, 0.723 mmol) was added. The suspension was gently stirred
for 18 h at rt and then puriﬁed by ion-exchange chromatography on
acidic resin (5 g), eluting with MeOH, 20% MeOH−CH2Cl2, and
then 1:1 CH2Cl2/7 M NH3 in MeOH. The basic fractions were
concentrated and dried in vacuo to give 3-bromo-6-chloro-N-
(tetrahydro-2H-pyran-4-yl)imidazo[1,2-b]pyridazin-8-amine (144
mg, 90%), which was used directly in the next step. A sample of
the crude material (60 mg, 0.18 mmol) was added to a mixture of 5-
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(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (53 mg,
0.216 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene (8.54 mg,
0.018 mmol), Pd(OAc)2 (4.04 mg, 0.018 mmol), and aq Na2CO3 (2
M; 0.360 mL, 0.720 mmol) in 1,4-dioxane (1.5 mL). The mixture was
heated in a sealed tube at 130 °C for 18 h and then cooled and
puriﬁed by ion-exchange chromatography on acidic resin (2 g),
eluting with MeOH and then with 1:1 CH2Cl2/7 M NH3 in MeOH.
The basic fractions were concentrated. Preparative HPLC, followed
by preparative thin-layer chromatography, eluting with 1% NH3 (aq)
in 7% MeOH−CH2Cl2, gave 19 (2.90 mg, 4%). 1H NMR (500 MHz,
MeOH-d4) δ 8.54 (dd, J = 0.9, 1.6 Hz, 1H), 8.14 (d, J = 1.0 Hz, 1H),
7.95 (dd, J = 1.6, 8.8 Hz, 1H), 7.81 (s, 1H), 7.63 (dt, J = 1.0, 8.9 Hz,
1H), 6.34 (s, 1H), 4.01 (dt, J = 3.7, 11.9 Hz, 2H), 3.84 (d, J = 10.4
Hz, 1H), 3.60 (td, J = 2.2, 11.6 Hz, 2H), 2.06 (ddt, J = 2.3, 4.6, 12.2
Hz, 2H), 1.69 (dtd, J = 4.3, 10.8, 13.2 Hz, 2H); 13C NMR (126 MHz,
MeOH-d4) δ 149.9, 143.4, 135.6, 134.5, 132.4, 131.1, 129.5, 127.6,
124.4, 122.6, 120.5, 111.3, 93.2, 67.4, 49.6 (2C), 33.3 (2C); LCMS (2
min) tR = 1.35 min, m/z (ESI
+) 369 (M + H+); HRMS m/z calcd for
C18H18N6O
35Cl (M + H) 369.1225, found 369.1216.
6-Chloro-3-(1H-indazol-5-yl)-N-(1-methylpiperidin-4-yl)imidazo-
[1,2-b]pyridazin-8-amine (20). Prepared from 3, 1-methylpiperidin-
4-amine, and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-in-
dazole using the method described for 19 to give 20 (11% over
two steps). 1H NMR (600 MHz, DMSO-d6) δ 13.2 (s, 1H), 8.51 (s,
1H), 8.20 (s, 1H), 8.00 (s, 1H), 7.98 (s, 1H), 7.74 (br d, J = 8.5 Hz,
1H), 7.67 (br d, J = 8.8 Hz, 1H), 6.40 (s, 1H), 3.66 (br s, 1H), 2.95−
2.93 (m, 2H), 2.33 (br s, 5H), 1.93−1.90 (m, 2H), 1.82−1.76 (m,
2H); 13C NMR (151 MHz, DMSO-d6) δ 148.1, 143.3, 139.6, 134.6,
133.3, 129.4, 129.3, 125.9, 123.4, 121.2, 118.9, 110.9, 91.4, 55.4, 54.2,
45.4, 34.2, 31.8 (2C); LCMS (2 min) tR = 0.94 min, m/z (ESI
+) 382
(M + H+); HRMS m/z calcd for C19H21N7
35Cl (M + H) 382.1547,
found 382.1542.
6-Chloro-3-(1H-indazol-5-yl)-N-((1-methylpiperidin-4-yl)-
methyl)imidazo[1,2-b]pyridazin-8-amine (21). Prepared from 3, (1-
methylpiperidin-4-yl)methanamine, and 5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indazole using the method described for 19 to
give 21 (10% over two steps). 1H NMR (500 MHz, MeOH-d4) δ 8.53
(t, J = 0.7 Hz, 1H), 8.14 (d, J = 0.9 Hz, 1H), 7.94 (dd, J = 1.6 and 8.8
Hz, 1H), 7.78 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 6.20 (s, 1H), 3.23 (d,
J = 7.0 Hz, 2H), 2.94 (br d, J = 12 Hz, 2H), 2.31 (s, 3H), 2.10−2.05
(m, 2H), 1.86 (br d, J = 13 Hz, 2H), 1.74−1.70 (m, 1H), 1.42−1.34
(m, 2H); 13C NMR (126 MHz, Methanol-d4) δ 148.4, 143.4, 139.6,
134.1, 133.0, 129.5, 128.1, 126.1, 122.9, 121.2, 118.9, 110.0, 91.4,
54.8, 44.8, 34.5, 29.2; LCMS (2 min) tR = 1.09 min, m/z (ESI
+) 396
(M + H+); HRMS m/z calcd for C20H23N7
35Cl (M + H) 396.1703,
found 396.1707.
(1r,4r)-N1-(6-Chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]pyridazin-
8-yl)cyclohexane-1,4-diamine (22). tert-Butyl ((1r,4r)-4-
aminocyclohexyl)carbamate (0.929 g, 4.34 mmol) was added to a
stirred solution of 3 (0.450 g, 1.45 mmol) in dimethylformamide (10
mL) at rt. The reaction was heated at 50 °C for 16 h, then cooled and
partitioned between Na2CO3 aq and EtOAc. The organic layer was
washed with brine, dried, and concentrated. Silica chromatography,
eluting with 0−40% EtOAc−cyclohexane, gave tert-butyl ((1r,4r)-4-
((3-bromo-6-chloroimidazo[1,2-b]pyridazin-8-yl)amino)cyclohexyl)-
carbamate (0.643 g, 100%). 1H NMR (500 MHz, CDCl3) δ 7.48 (s,
1H), 6.16 (s, 1H), 5.97 (d, J = 7.7 Hz, 1H), 4.08 (d, J = 13.4 Hz, 1H),
3.79 (s, 1H), 3.56 (s, 1H), 3.11 (ddd, J = 13.1, 9.6, 3.4 Hz, 1H), 3.03
(dd, J = 13.3, 8.5 Hz, 1H), 2.16−2.09 (m, 1H), 1.84 (d, J = 14.3 Hz,
1H), 1.75−1.64 (m, 2H), 1.48 (s, 9H); LCMS (2 min) tR = 1.57 min
m/z, (ESI+) 446 (M + H+). A mixture of tert-butyl ((1r,4r)-4-((3-
bromo-6-chloroimidazo[1,2-b]pyridazin-8-yl)amino)cyclohexyl)-car-
bamate (0.100 g, 0.225 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)-1H-indazole (0.055 g, 0.225 mmol), Pd(OAc)2 (5.05 mg,
0.022 mmol), 1,1′-bis(di-t-butylphosphino)ferrocene (0.011 g, 0.022
mmol), and Na2CO3 aq (2 M; 0.45 mL, 0.900 mmol) in 1,4-dioxane
(2 mL) was heated at 130 °C in a sealed tube for 24 h. The mixture
was cooled, ﬁltered through celite, and absorbed onto silica.
Chromatography, eluting with 0−50% EtOAc−cyclohexane, gave
tert-butyl ((1r,4r)-4-((6-chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]-
pyridazin-8-yl)amino)cyclohexyl)carbamate (0.060 g, 55%). 1H
NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 8.22 (s, 1H), 7.94 (d, J
= 8.7 Hz, 1H), 7.74 (s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 6.18 (d, J = 8.0
Hz, 1H), 6.04 (d, J = 7.0 Hz, 1H), 4.54−4.47 (m, 1H), 3.54 (s, 1H),
3.47−3.37 (m, 1H), 2.52−2.12 (m, 4H), 1.48 (s, 9H), 1.37−1.24 (m,
4H); LCMS (2 min) tR = 1.56 min m/z, (ESI
+) 482 (M + H+). tert-
Butyl ((1r,4r)-4-((6-chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]-
pyridazin-8-yl)amino)cyclohexyl)carbamate (30 mg, 0.062 mmol)
was dissolved in HCl−1,4-dioxane (4 M; 1 mL) and stirred at rt for 2
h. The mixture was concentrated. Ion-exchange chromatography on
acidic resin, eluting with 2 M NH3−MeOH, followed by preparative
HPLC gave 22 (24 mg, 99%). 1H NMR (500 MHz, DMSO-d6) δ
8.50 (t, J = 1.2 Hz, 1H), 8.19 (d, J = 1.0 Hz, 1H), 7.96−7.89 (m, 2H),
7.69−7.62 (m, 1H), 7.55 (s, 1H), 6.34 (s, 1H), 3.52 (s, 1H), 3.17 (br
s, 3H), 2.57 (tt, J = 10.5, 3.6 Hz, 1H), 1.99−1.71 (m, 4H), 1.50 (q, J
= 13.3, 12.7 Hz, 2H), 1.25−1.15 (m, 2H); 13C NMR (126 MHz,
DMSO-d6) δ 165.6, 147.7, 142.78, 139.3, 134.0, 132.8, 128.9, 125.4,
122.9, 120.8, 118.4, 110.6, 90.9, 49.7, 48.5, 29.5 (2C), 29.3 (2C);
LCMS (2 min) tR = 1.11 min, m/z, (ESI
+), 382 (M + H+); HRMS m/
z calcd for C19H20N7
35Cl (M + H) 382.1547, found 382.1538.
(1r,4r)-N1-(6-Chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]pyridazin-
8-yl)-N1-methylcyclohexane-1,4-diamine (23). LiAlH4 in THF (1
M; 25 mL, 25.0 mmol) was added to a solution of tert-butyl ((1r,4r)-
4-aminocyclohexyl)carbamate (1.30 g, 6.07 mmol) in THF (5 mL) at
0 °C. The mixture was heated to reﬂux for 4 h, forming a thick white
suspension. The reaction was cooled, diluted with Et2O (80 mL), and
water (0.95 mL) was slowly added dropwise, followed by 15% w/v
NaOH aq (0.95 mL). After stirring for 1 h, water (2.85 mL) was
added dropwise. The mixture was ﬁltered through celite, washed with
Et2O, and the ﬁltrate was concentrated to give crude (1r,4r)-N
1-
methylcyclohexane-1,4-diamine (0.597 g). A solution of the crude
amine, Et3N (1.3 mL, 9.31 mmol), and ethyl 1,3-dioxoisoindoline-2-
carboxylate (0.928 g, 4.23 mmol) in CH2Cl2 (42 mL) was stirred at rt
for 15 h. Saturated (NH4)2CO3 aq (50 mL) was added, and the
mixture was extracted with CH2Cl2 (3 × 30 mL). The combined
organic layers were dried and concentrated to give crude 2-((1r,4r)-4-
(methylamino)cyclohexyl)isoindoline-1,3-dione (0.99 g). A mixture
of the crude amine, 3 (0.918 g, 2.95 mmol), and Et3N (0.82 mL, 5.90
mmol) in 1,4-dioxane (3.7 mL) and DMSO (3.7 mL) was heated at
100 °C for 21 h. The mixture was cooled and diluted with CH2Cl2
(15 mL). The solid was collected and washed with dichloromethane
(DCM, 5 mL) to give 2-((1r,4r)-4-((3-bromo-6-chloroimidazo[1,2-
b]pyridazin-8-yl)(methyl)amino)cyclohexyl)isoindoline-1,3-dione
(1.06 g, 52% over three steps). 1H NMR (500 MHz, DMSO-d6) δ
7.88−7.82 (m, 4H), 7.80 (s, 1H), 6.26 (s, 1H), 5.76 (br s, 1H), 4.18−
4.08 (m, 1H), 3.10 (br s, 3H), 2.39−2.25 (m, 2H), 1.97−1.77 (m,
6H); LCMS (4 min) tR = 3.53 min, m/z (ESI
+) 490 (M + H+). A
mixture of 2-((1r,4r)-4-((3-bromo-6-chloroimidazo[1,2-b]pyridazin-
8-yl)(methyl)amino)cyclohexyl)-isoindoline-1,3-dione (0.210 g,
0.430 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-in-
dazole (0.126 g, 0.516 mmol), Pd(OAc)2 (9.6 mg, 0.043 mmol), 1,1′-
bis(di-tert-butylphosphino)ferrocene (0.020 g, 0.043 mmol), and
Na2CO3 aq (2 M; 0.86 mL, 1.72 mmol) in 1,4-dioxane (2.1 mL) was
heated at 130 °C for 21 h. The reaction mixture was cooled and
NH2NH2·H2O (0.5 mL) was added. The mixture was heated at 100
°C for 48 h. The mixture was cooled and puriﬁed by ion-exchange
chromatography on acidic resin, eluting with 2 M NH3 in MeOH.
Reversed-phase silica chromatography, eluting with 10−90% MeOH−
water containing 0.1% HCO2H, followed by normal phase
chromatography, eluting with 2−20% EtOH−CH2Cl2, gave 23
(0.058 g, 34%). 1H NMR (600 MHz, DMSO-d6) δ 13.20 (s, 1H),
8.47−8.44 (m, 1H), 8.20 (d, J = 0.9 Hz, 1H), 7.96 (s, 1H), 7.90 (dd, J
= 8.7, 1.6 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 6.19 (s, 1H), 5.70 (br s,
1H), 3.07 (br s, 3H), 2.57 (tt, J = 11.1, 3.9 Hz, 1H), 1.88−1.81 (m,
2H), 1.76−1.70 (m, 4H), 1.62 (br s, 2H), 1.32−1.18 (m, 2H); 13C
NMR (151 MHz, DMSO-d6) δ 147.6, 145.1, 139.7, 134.5, 133.7,
129.3, 128.9, 126.3, 123.3, 121.2, 119.4, 110.9, 94.1, 57.9, 50.0, 35.8
(2C), 32.7, 28.9 (2C); LCMS (4 min) tR = 2.26 min, m/z (ESI
+) 396
(M + H+); HRMS m/z calcd for C20H22N7
35Cl (M + H) 396.1703,
found 396.1700.
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N-(trans-4-((6-Chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]-
pyridazin-8-yl)amino)cyclohexyl)acetamide (24). Prepared from 3,
N-((1r,4r)-4-aminocyclohexyl)acetamide, and 5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1H-indazole using the methods described for
19, except that the ﬁrst step was conducted at 50 °C, to give 24 (35%
over two steps). 1H NMR (500 MHz, DMSO-d6) δ 13.18 (s, 1H),
8.50 (dt, J = 0.8, 1.6 Hz, 1H), 8.19 (t, J = 1.3 Hz, 1H), 7.96−7.90 (m,
2H), 7.80 (d, J = 7.7 Hz, 1H), 7.65 (dt, J = 0.9, 8.7 Hz, 1H), 7.61 (d, J
= 8.8 Hz, 1H), 6.42 (s, 1H), 3.60 (s, 1H), 3.50 (dtt, J = 4.1, 8.1, 11.9
Hz, 1H), 1.93 (t, J = 8.2 Hz, 2H), 1.79 (s, 5H), 1.56 (d, J = 12.8 Hz,
2H), 1.41−1.27 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 168.3,
147.7, 142.8, 139.1, 134.2, 132.9, 128.9, 128.8, 125.5, 122.9, 120.8,
118.4, 110.4, 90.7, 50.1, 47.2, 30.9 (2C), 30.3 (2C), 22.8; LCMS (2
min), tR = 1.32 min, m/z (ESI
+) 424 (M + H+); HRMS m/z calcd for
C21H23N7O
35Cl (M + H) 424.1647, found 424.1635.
6-Chloro-3-(1H-indazol-5-yl)-N-(trans-4-morpholinocyclohexyl)-
imidazo[1,2-b]pyridazin-8-amine, Formate Salt (25). Prepared from
3, (1r,4r)-4-morpholinocyclohexan-1-amine, and 5-(4,4,5,5-tetra-
methyl-1,3,2-dioxaborolan-2-yl)-1H-indazole using the methods
described for 19, except that the ﬁrst step was conducted at 50 °C,
to give 25 (4% over two steps), isolated as the formate salt from
preparative HPLC. 1H NMR (500 MHz, MeOH-d4) δ 8.56−8.52 (m,
1H), 8.36 (s, 1H), 8.14 (d, J = 1.0 Hz, 1H), 7.94 (dd, J = 1.6, 8.8 Hz,
1H), 7.79 (s, 1H, formate), 7.63 (d, J = 8.6 Hz, 1H), 6.26 (s, 1H),
3.88 (t, J = 4.7 Hz, 4H), 3.55−3.51 (m, 1H), 3.13 (t, J = 4.6 Hz, 4H),
3.00 (ddd, J = 3.3, 8.4, 12.1 Hz, 1H), 2.28−2.15 (m, 4H), 1.63 (qd, J
= 3.2, 12.6 Hz, 2H), 1.46 (qd, J = 2.9, 13.1 Hz, 2H); 13C NMR (126
MHz, MeOH-d4) δ 167.8 (formate), 149.8, 143.5, 141.1, 135.5, 134.4,
131.0, 129.6, 127.5, 124.4, 122.6, 120.4, 111.4, 93.1, 65.9 (2C), 65.4,
51.4, 50.4 (2C), 31.4 (2C), 26.6 (2C); LCMS (2 min), tR = 1.00 min,
m/z (ESI+) 452 (M + H+); HRMS m/z calcd for C23H27N7O
35Cl (M
+ H) 452.1966, found 452.1961.
2-(((1r,4r)-4-((6-Chloro-3-(1H-indazol-5-yl)imidazo[1,2-b]-
pyridazin-8-yl)amino)cyclohexyl)amino)-1-morpholinoethan-1-
one (26). A solution of 2-chloro-1-morpholinoethanone (0.66 mL,
5.05 mmol), tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (902
mg, 4.21 mmol), and Et3N (2.1 mL, 15.1 mmol) in CH2Cl2 (35 mL)
was stirred at rt for 20 h. The mixture was partitioned between water
(50 mL) and CH2Cl2 (30 mL × 2). The combined organic layers
were dried and concentrated. The resulting crude material was
dissolved in MeOH (42 mL), and HCl in 1,4-dioxane (4 M; 42 mL,
168 mmol) was added. After 2 h at rt, the mixture was concentrated
and puriﬁed by ion-exchange chromatography on acidic resin, eluting
with 2 M NH3 in MeOH, to give 2-(((1r,4r)-4-aminocyclohexyl)-
amino)-1-morpholinoethan-1-one (0.375 g, 37%). 1H NMR (500
MHz, CDCl3) δ 3.71−3.59 (m, 7H), 3.49−3.36 (m, 4H), 2.72−2.58
(m, 3H), 2.42−2.33 (m, 1H), 1.94−1.78 (m, 4H), 1.24−1.04 (m,
4H). A sample of the material (0.370 g, 1.55 mmol), 3 (0.440 g, 1.41
mmol), and Et3N (0.39 mL, 2.83 mmol) in 1,4-dioxane (1.8 mL) and
DMSO (1.8 mL) was heated at 50 °C for 23 h. The mixture was
cooled and puriﬁed by ion-exchange chromatography on acidic resin,
eluting with 2 M NH3 in MeOH, and then by silica chromatography,
eluting with 2−20% EtOH−CH2Cl2, to give 2-(((1r,4r)-4-((3-bromo-
6-chloroimidazo[1,2-b]pyridazin-8-yl)amino)cyclohexyl)amino)-1-
morpholinoethan-1-one (0.38 g, 58%). 1H NMR (500 MHz, CDCl3)
δ 7.44 (s, 1H), 6.04 (s, 1H), 5.80 (d, J = 8.1 Hz, 1H), 3.75−3.62 (m,
7H), 3.47 (s, 2H), 3.43−3.40 (m, 3H), 2.56−2.47 (m, 1H), 2.23−
2.15 (m, 2H), 2.10−2.01 (m, 2H), 1.43−1.29 (m, 4H); LCMS (2
min) tR = 0.97 min, m/z (ESI
+) 473 (M + H+). A sample of the
material (0.365 g, 0.774 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazole (0.227 g, 0.928 mmol), Pd(OAc)2 (17.0
mg, 0.077 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene (37.0 mg,
0.077 mmol), and Na2CO3 aq (2 M; 1.55 mL, 3.09 mmol) were
mixed in 1,4-dioxane (3.9 mL) and heated at 135 °C for 19 h. The
mixture was cooled and puriﬁed by ion-exchange chromatography on
acidic resin, eluting with 2 M NH3 in MeOH, then by silica
chromatography, eluting with 2−20% MeOH-CH2Cl2, and then by
reversed-phase chromatography, eluting with 10−70% MeOH−water
with 0.1% formic acid, to give 26 (0.069 g, 18%). 1H NMR (500
MHz, MeOH-d4) δ 8.49 (dd, J = 1.6, 0.9 Hz, 1H), 8.11 (d, J = 1.0 Hz,
1H), 7.89 (dd, J = 8.8, 1.6 Hz, 1H), 7.72 (s, 1H), 7.59 (d, J = 8.7 Hz,
1H), 6.17 (s, 1H), 3.67−3.63 (m, 4H), 3.59−3.55 (m, 2H), 3.46 (s,
2H), 3.45−3.42 (m, 3H), 2.50−2.41 (m, 1H), 2.13−2.06 (m, 2H),
2.02−1.96 (m, 2H), 1.40−1.24 (m, 4H); 13C NMR (126 MHz,
MeOH-d4) δ 171.2, 149.8, 143.5, 141.0, 135.5, 134.4, 130.9, 129.4,
127.5, 124.4, 122.6, 120.3, 111.3, 92.9, 67.7, 67.6, 57.2, 52.2, 48.0,
46.1, 43.4, 32.0 (2C), 31.6 (2C); LCMS (2 min) tR = 1.05 min, m/z
(ESI+) 509 (M + H+); HRMS m/z calcd for C25H30N8O2
35Cl (M +
H) 509.2180, found 509.2187.
6-Chloro-3-(2-(phenylamino)-1H-benzo[d]imidazol-5-yl)-N-(tet-
rahydro-2H-pyran-4-yl)imidazo[1,2-b]pyridazin-8-amine (27). Pre-
pared from 4, tetrahydro-2H-pyran-4-amine, and 13 using the method
described for 19 to give 27 (14% over two steps). 1H NMR (500
MHz, DMSO-d6) δ 11.13 and 11.01 (2 × s, 1H, NH); 9.53 and 9.50
(2 × s, 1H, NH), 8.06 (dd, J = 1.7, 12.9 Hz, 1H), 7.87 (d, J = 11.0 Hz,
1H), 7.82−7.75 (m, 2H), 7.71 (dd, J = 6.7, 8.7 Hz, 1H), 7.64−7.58
(m, 1H), 7.41 (dd, J = 8.3, 28.4 Hz, 1H), 7.36−7.29 (m, 2H), 6.94
(tt, J = 1.2, 7.3 Hz, 1H), 6.43 (s, 1H), 3.83−3.96 (m, 2H), 3.45 (td, J
= 2.0, 11.7 Hz, 2H), 3.33 (s, 1H), 1.92−1.79 (m, 2H), 1.78−1.64 (m,
2H); 13C NMR (126 MHz, DMSO-d6) δ 151.4, 151.2, 147.5, 143.2,
143.1, 142.6, 140.7, 132.9, 132.6, 129.7, 128.8 (2C), 128.5, 120.9,
120.7, 120.0, 117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.6, 66.0
(2C), 48.2, 31.8 (2C); LCMS (4 min) tR = 2.60 min, m/z (ESI
+) 460
(M + H+); HRMS m/z calcd for C24H22N7O
35Cl (M + H) 460.1653,
found 460.1651.
6-Chloro-N-(1-methylpiperidin-4-yl)-3-(2-(phenylamino)-1H-
benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine (28). Pre-
pared from 3, 1-methylpiperidin-4-amine, and 13 using the method
described for 19 to give 28 (5% over two steps). 1H NMR (500 MHz,
DMSO-d6) δ 11.14 and 11.02 (2 × s, 1H, NH), 9.54 and 9.51 (2 × s,
1H, NH), 8.11−8.10 (m, 1H), 7.86 (d, J = 10.6 Hz, 1H), 7.78 (d, J =
7.9 Hz, 2H), 7.65−7.57 (m, 2H), 7.41 (dd, J = 8.3, 28.5 Hz, 1H),
7.36−7.28 (m, 2H), 6.97−6.90 (m, 1H), 6.35 (s, 1H), 3.57 (d, J = 2.3
Hz, 1H), 2.80 (d, J = 11.1 Hz, 2H), 2.21 (s, 3H), 2.08 (t, J = 11.7 Hz,
2H), 1.86 (d, J = 12.2 Hz, 2H), 1.80−1.67 (m, 2H); 13C NMR (126
MHz, DMSO-d6) δ 151.4, 151.2, 147.5, 143.2, 143.1, 142.8, 140.7,
132.9, 132.6, 129.7, 128.8 (2C), 128.4, 120.9, 120.7, 119.9, 119.0,
117.2 (2C), 117.1, 115.8, 114.2, 109.5, 107.7, 90.6, 54.1 (2C), 48.8,
45.8, 30.7 (2C); LCMS (2 min) tR = 0.86 min, m/z (ESI
+) 473 (M +
H+); HRMS m/z calcd for C25H25N8
35Cl (M + H) 473.1969, found
473.1961.
6-Chloro-N-((1-methylpiperidin-4-yl)methyl)-3-(2-(phenylami-
no)-1H-benzo[d]imidazol-5-yl)imidazo[1,2-b]pyridazin-8-amine
(29). Prepared from 3, (1-methylpiperidin-4-yl)methanamine, and 13
using the method described for 19 to give 29 (13% over two steps).
1H NMR (500 MHz, DMSO-d6) δ 11.19 and 11.07 (2 × s, 1H, NH),
9.57 and 9.54 (2 × s, 1H, NH), 8.05 (d, J = 13.4 Hz, 1H), 7.93 (s,
1H), 7.85 (d, J = 9.2 Hz, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.61 (d, J =
8.2 Hz, 1H), 7.40 (dd, J = 8.2, 9.4 Hz, 1H), 7.32 (t, J = 7.8 Hz, 2H),
6.93 (tt, J = 1.2, 7.3 Hz, 1H), 6.30 (s, 1H), 3.23 (s, 2H), 2.79 (d, J =
11.2 Hz, 2H), 2.17 (s, 3H), 1.96−1.81 (m, 2H), 1.74−1.60 (m, 3H),
1.32−1.16 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 151.4, 151.3,
147.5, 143.9, 143.2, 143.1, 140.8, 132.9, 132.6, 129.7, 128.8 (2C),
128.4, 120.7, 119.9, 119.0, 117.2 (2C), 115.8, 114.2, 109.5, 107.7,
90.3, 54.9 (2C), 47.2, 45.9, 34.2, 29.4 (2C); LCMS (2 min) tR = 1.03
min, m/z (ESI+) 487 (M + H+); HRMS m/z calcd for C26H27N8
35Cl
(M + H) 487.2125, found 487.2130.
6-Chloro-3-(7-ﬂuoro-2-(phenylamino)-1H-benzo[d]imidazol-5-
yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-
amine (30). Prepared from 5-bromo-3-ﬂuorobenzene-1,2-diamine
and 3-bromo-6-chloro-N-((1-methylpiperidin-4-yl)methyl)imidazo-
[1,2-b]pyridazin-8-amine using the method described for 31 to give
30 (5% over 4 steps). 1H NMR (500 MHz, DMSO-d6) δ 11.67 (s,
1H), 9.82 (s, 1H), 7.97 (t, J = 6.5 Hz, 1H), 7.94 (s, 2H), 7.83−7.72
(m, 2H), 7.54 (d, J = 12.2 Hz, 1H), 7.39−7.29 (m, 2H), 6.96 (tt, J =
1.2, 7.3 Hz, 1H), 6.33 (s, 1H), 3.24 (s, 2H), 2.80 (d, J = 11.2 Hz, 2H),
1.88 (t, J = 11.5 Hz, 2H), 2.18 (s, 3H), 1.77−1.61 (m, 3H), 1.32−
1.17 (m, 2H); 13C NMR (151 MHz, DMSO-d6) δ 152.0, 148.1,
144.3, 140.9, 133.4, 129.5, 129.3 (2C), 128.9, 121.5, 120.8, 117.9
(2C), 105.8 (d, JC−F = 16.6 Hz), 104.5, 91.0, 55.5 (2C), 47.8, 46.6,
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34.8, 30.0 (2C) (3 quaternary C not observed); LCMS (2 min) tR =
1.13 min, m/z (ES+) 505 (M + H+); HRMS m/z calcd for
C26H26N8F
35Cl (M + H) 505.2031, found 505.2036.
6-Chloro-3-(6-ﬂuoro-2-(phenylamino)-1H-benzo[d]imidazol-5-
yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-
amine (31). A mixture of (1-methylpiperidin-4-yl)methanamine (1.24
g, 9.64 mmol), 3 (2.00 g, 6.42 mmol), and Et3N (1.79 mL, 12.9
mmol) in 1,4-dioxane (4 mL) and DMSO (4 mL) was stirred at 50
°C for 18 h. The mixture was cooled, diluted with EtOAc, and the
organic layer was washed sequentially with water and brine. The
organic layer was dried and concentrated. Ion-exchange chromatog-
raphy on acidic resin, eluting with 2 M NH3 in MeOH, followed by
silica chromatography, eluting with 0−5% MeOH−CH2Cl2 and then
with 5−10% MeOH−DCM + 0.2 M NH3, gave 3-bromo-6-chloro-N-
((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine
(2.00 g, 87%), which was used directly in subsequent steps. LCMS (2
min) tR = 0.84 min, m/z (ESI
+) 360 (M + H+). Separately,
isothiocyanatobenzene (1.22 mL, 10.2 mmol) and EDC (3.37 g, 17.5
mmol) were added to a stirred solution of 4-bromo-5-ﬂuorobenzene-
1,2-diamine (2.00 g, 9.75 mmol) in dry THF (100 mL) at rt. The
mixture was heated at 50 °C for 4 h, cooled, and concentrated. The
residue was partitioned between water (100 mL) and EtOAc (100
mL). The organic layer was washed with brine (100 mL), dried, and
concentrated. Ion-exchange chromatography on acidic resin, eluting
with MeOH, gave 5-bromo-6-ﬂuoro-N-phenyl-1H-benzo[d]imidazol-
2-amine that was used directly in the next step (2.53 g, 85%). 1H
NMR (500 MHz, DMSO-d6) δ 11.10 and 10.99 (2 × s, 1H, NH),
9.61 and 9.58 (2 × s, 1H, NH), 7.74−7.60 (m, 2H), 7.60−7.45 (m,
1H), 7.35−7.23 (m, 3H), 6.95 (t, J = 7.3 Hz, 1H); 13C NMR (126
MHz, DMSO-d6) δ 154.6, 152.5, 152.0, 143.4, 140.3, 130.4, 128.8
(2C), 121.15, 121.1, 118.5, 117.4 (2C), 117.3, 112.3, 103.2 (d, J =
26.0 Hz), 97.8 (d, J = 26.0 Hz), (1 quaternary C not observed);
LCMS (2 min) tR = 1.01 min, m/z (ESI
+) 306 (M + H+); HRMS m/z
calcd for C13H9N3F
79Br (M + H) 306.0042, found 306.0047. A
mixture of 5-bromo-6-ﬂuoro-N-phenyl-1H-benzo[d]imidazol-2-amine
(2.53 g, 8.26 mmol), (Boc)2O (4.50 g, 20.7 mmol), and DMAP (0.20
g, 1.65 mmol) in THF (80 mL) was stirred at rt for 16 h. The mixture
was concentrated, and the residue was partitioned between EtOAc
(100 mL) and water (100 mL). The organic layer was washed with
brine (100 mL), dried, and concentrated. Silica chromatography,
eluting with 0−10% EtOAc−cyclohexane, gave the product as a
mixture of three diﬀerent di-Boc-protected positional isomers (1.94
g), which was used as such in the next step. LCMS (2 min) tR = 1.68,
1.79, and 1.92 min, m/z (ESI+) 506 (M + H+). This material (1.94 g)
was stirred at rt in 1,4-dioxane (42 mL), and bis(pinacolato)diboron
(1.17 g, 4.59 mmol), PdCl2dppf (0.28 g, 0.38 mmol), and KOAc
(0.75 g, 7.65 mmol) were added. The mixture was heated at 120 °C
for 24 h, then cooled and ﬁltered through celite. The ﬁltrate was
concentrated and dissolved in THF (80 mL). DMAP (0.093 g, 0.77
mmol) and (Boc)2O (1.67 g, 7.66 mmol) were added, and the
mixture was stirred for 6 h at rt. Solvent was removed by evaporation,
and the residue was partitioned between water (100 mL) and EtOAc
(100 mL). The organic layer was washed with brine (100 mL), dried,
and concentrated. Silica chromatography, eluting with 0−50% EtOAc-
cyclohexane, gave the product as a mixture of three diﬀerent di-Boc-
protected positional isomers (1.08 g), which was used as such in the
next step. LCMS (2 min) tR = 1.67, 1.78, and 1.81 min, m/z (ESI
+)
554 (M + H+). A mixture of this material (1.08 g), 3-bromo-6-chloro-
N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine
(0.63 g, 1.76 mmol) and Na2CO3 aq (2 M; 3.51 mL, 7.03 mmol) in
dry 1,4-dioxane (18 mL) was purged with N2 for 10 min. Pd(OAc)2
(0.079 g, 0.35 mmol) and 1,1′-bis(di-tert-butylphosphino)ferrocene
(0.17 g, 0.35 mmol) were added and the tube was sealed and stirred at
135 °C for 15 h. The mixture was cooled, ﬁltered through celite pad,
and concentrated. The residue was puriﬁed by silica chromatography,
eluting with 0−5% MeOH−CH2Cl2 and then with 5−10% MeOH−
CH2Cl2 + 1% 0.2 M NH3 aq, to give 31 (100 mg, 3% over three
steps). 1H NMR (500 MHz, DMSO-d6) δ 11.14 (s, 1H), 9.62 (s,
1H), 8.00 (d, J = 6.5 Hz, 1H), 7.82 (d, J = 6.6 Hz, 1H), 7.79−7.74
(m, 2H), 7.70 (d, J = 2.5 Hz, 1H), 7.35−7.31 (m, 2H), 7.28 (d, J =
11.1 Hz, 1H), 6.98−6.92 (m, 1H), 6.31 (s, 1H), 3.23 (s, 2H), 2.75 (d,
J = 10.8 Hz, 2H), 2.13 (s, 3H), 1.87−1.73 (m, 2H), 1.73−1.59 (m,
3H), 1.31−1.16 (m, 2H); 13C NMR (151 MHz, DMSO-d6) δ 154.1
(d, JC−F = 257.2 Hz), 148.1, 144.3, 140.9, 132.9, 131.0, 129.8, 129.3
(2C), 124.5, 121.5, 117.9 (2C), 110.0, 102.8, 91.1, 55.5 (2C), 47.8,
46.6, 34.8, 30.1 (2C) (3 quaternary C not observed); LCMS (2 min)
tR = 0.91 min, m/z (ESI
+) 505 (M + H+); ESI m/z calcd for
C26H26N8F
35Cl (M + H) 505.2031, found 505.2036.
6-Chloro-3-(4-ﬂuoro-2-(phenylamino)-1H-benzo[d]imidazol-5-
yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-
amine (32). Prepared from 4-bromo-3-ﬂuorobenzene-1,2-diamine
and 3-bromo-6-chloro-N-((1-methylpiperidin-4-yl)methyl)imidazo-
[1,2-b]pyridazin-8-amine using the method described for 31 to give
32 (2% over four steps). 1H NMR (500 MHz, DMSO-d6) δ 11.38 (s,
1H), 9.62 (s, 1H), 7.99 (t, J = 6.3 Hz, 1H), 7.81−7.74 (m, 2H), 7.69
(d, J = 1.4 Hz, 1H), 7.38 (t, J = 7.3 Hz, 1H), 7.36−7.32 (m, 2H), 7.25
(d, J = 8.2 Hz, 1H), 6.96 (tt, J = 1.2, 7.3 Hz, 1H), 6.29 (s, 1H), 3.23
(s, 2H), 2.79−2.68 (m, 2H), 2.13 (s, 3H), 1.86−1.74 (m, 2H), 1.73−
1.60 (m, 3H), 1.30−1.16 (m, 2H); 13C NMR (151 MHz, DMSO-d6)
δ 151.9, 148.1, 144.3, 140.9, 133.0, 130.7, 129.3 (2C), 124.8, 122.0,
121.4, 117.8 (2C), 107.9, 106.2, 91.1, 55.4 (2C), 47.7, 46.4, 34.7, 29.9
(2C) (3 quaternary C not observed); LCMS (2 min) tR = 1.14 min,
m/z (ESI+) 505 (M + H+); HRMS m/z calcd for C26H26N8F
35Cl (M
+ H) 505.2031, found 505.2013.
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